# TO EVALUATE THE EFFECT OF CLONIDINE AS AN ADJUVANT TO 0.5% ROPIVACAINE IN ERECTOR SPINAE PLANE BLOCK FOR POSTOPERATIVE ANALGESIA IN BREAST SURGERIES: A RANDOMISED CONTROLLED TRIAL



#### **THESIS**

#### **Submitted to**

All India Institute of Medical Sciences, Jodhpur
In partial fulfillment of the requirement for the degree of
DOCTOR OF MEDICINE (MD)
ANAESTHESIOLOGY AND CRITICAL CARE

JULY 2020 AIIMS, JODHPUR **Dr. SHREYA NEOGY** 

# **DECLARATION**



I hereby declare that the thesis titled "TO EVALUATE THE EFFECT OF CLONIDINE AS AN ADJUVANT TO 0.5% ROPIVACAINE IN ERECTOR SPINAE PLANE BLOCK FOR POSTOPERATIVE ANALGESIA IN BREAST SURGERIES:A RANDOMISED CONTROLLED TRIAL" embodies the original work carried out by me at All India Institute of Medical Sciences, Jodhpur

Shreya Newgy

**Dr. SHREYA NEOGY** 

Department of Anaesthesiology & Critical Care All India Institute of Medical Sciences, Jodhpur

# **CERTIFICATE**

This is to certify that the thesis titled "TO EVALUATE THE EFFECT OF CLONIDINE AS AN ADJUVANT TO 0.5% ROPIVACAINE IN ERECTOR SPINAE PLANE BLOCK FOR POSTOPERATIVE ANALGESIA IN BREAST SURGERIES:A RANDOMISED CONTROLLED TRIAL" is the bonafide work of DR. SHREYA NEOGY carried out under our guidance and supervision, at Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur.

#### **Guide:**

Bharat Paliwol

Dr. BHARAT PALIWAL

Additional Professor

Department of Anaesthesiology & Critical Care

All India Institute of Medical Sciences, Jodhpur

#### **Co-Guides:**

Dr. PrageepKumar Bhatia

Professor\& Head,

Department of Anaesthesiology &

Critical Care.

AIIMS, Jodhpur

Dr. Manoj Kamal

Additional Professor,

Department of Anaesthesiology

& Critical Care.

AIIMS, Jodhpur

Dr. Sadik Mohammed

Additional Professor,

Department of

Anaesthesiology&Critical

Care.AIIMS, Jodhpur

Dr. Rakesh Kumar

Rosesh Kurrer

AssociateProfessor,Departmentof

Anaesthesiology & Critical

Care.AIIMS, Jodhpur



# **CERTIFICATE**

This is to certify that the thesis titled "TO EVALUATE THE EFFECT OF CLONIDINE AS AN ADJUVANT TO 0.5% ROPIVACAINE IN ERECTOR SPINAE PLANE BLOCK FOR POSTOPERATIVE ANALGESIA IN BREAST SURGERIES:A RANDOMISED CONTROLLED TRIAL" is the bonafide work of Dr. SHREYA NEOGY carried out at Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur.

Dr Pradeep Kumar Bhatia

Professor and Head,

Department of Anaesthesiology & Critical Care

All India Institute of Medical Sciences, Jodhpur.

# **ACKNOWLEDGEMENT**

"Individually, we are one drop. Together, we are an ocean."

#### Ryunosuke Satoro

Nothing worthwhile has ever been accomplished without the guidance and encouragement of our teachers and the support of our family and friends. As I stand on the verge of one of my life's most distinguished accomplishments, Ryunosuke Satoro's words ring truer than ever.

This dissertation might never have seen the light of day without the trust, confidence and patient patronage of Dr. Bharat Paliwal, my MD thesis Guide and Additional Professor in the Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur. I feel truly privileged and incredibly grateful for the opportunity to learn under his mentorship. I am extremely thankful to him for devoting his valuable time out of his busy schedule and guiding this project towards completion.

I express my heartfelt gratitude to the Dr Pradeep Kumar Bhatia, Professor and Head, Department of Anaesthesiology and Critical Care, AIIMS, Jodhpur, who has nurtured such a wonderful department such as ours, which fosters imagination, innovation, and a sense of ethics in all of us.

I am deeply indebted to my Co-guides Dr.Manoj Kamal, Additional Professor, Dr.Sadik Mohammed, Additional Professor and Dr.Rakesh Kumar, Associate Professor of the Department of Anaesthesiology and Critical Care, AIIMS Jodhpur. Their step-by-step advice and guidance have been invaluable in establishing the environment of success and excellence required for completion of this dissertation.

All the faculties of the Department of Anesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur have been pillars of support and understanding and this would not have been possible without them. I acknowledge the nurturance I have received from my seniors of the Department of Anaesthesiology. Without their help and reprimands, I would have been clueless as to how to proceed with the work involved in this dissertation. I also thank my lovely juniors who have stepped up in times of need to help me in completing my

thesis. I would like to acknowledge the sincerity and hardwork all the nursing staffs and

anaesthesia technicians for helping me in carrying out my project. My friends have also

played a crucial part in this endeavor by always encouraging me to chase excellence and by

lending me their patient ears. Their words of motivation has helped me sail through several

difficult times.

I want to express my sincere gratitude towards Dr Akhil Dhanesh Goel, Associate Professor,

Department of Community Medicine and Family Medicine, AIIMS Jodhpur for his immense

contribution towards the statistical workup of my thesis, without which my thesis would have

been incomplete.


The love of one's family is life's greatest blessing. Words fall short when I begin to express

my appreciation and love for my parents, Mr. Amitava Neogy and Mrs Shrabani Neogy and

my brother Mr. Arna Neogy having my back through out and for always being so

understanding and supportive throughout my life.

**Dr. SHREYA NEOGY** 



# **INDEX**

SECTION	PAGE NO.
LIST OF ABBREVIATIONS	i
LIST OF TABLES	ii-iii
LIST OF FIGURES	iv-v
SUMMARY	vi-vii
INTRODUCTION	1-4
AIM AND OBJECTIVES	5
REVIEW OF LITERATURE	6-12
MATERIALS AND METHODS	13-15
RESULTS	16-40
DISCUSSION	41-47
CONCLUSION	48
STRENGTH AND LIMITATIONS	49
BIBLIOGRAPHY	50-54
Annexure	55-62
IEC certificate	55
Informed consent form (English)	56
Informed consent form (Hindi)	57
Patient information sheet (English)	58
Patient information sheet (Hindi)	59
Proforma	60-61
Master Chart	62

# **LIST OF ABBREVIATIONS**

- HR: Heart rate
- SBP: Systolic blood pressure
- DBP:Diastolic blood pressure
- MAP: Mean arterial blood pressure
- SpO2:Saturation of oxygen
- NIBP:Non-invasive blood pressure
- SD:Standard deviation
- ESP: Erector spinae plane
- TPVB:Thoracic paravertebral block
- MRM:Modified radical mastectomy
- VAS:Visual analogue scale
- ASA: American society of anaesthesiologists
- PECS:Pectoralis
- ECG:Electrocardiogram
- VATLS: Video assisted thoracoscopic lobectomy surgery
- PCA: Patient controlled analgesia
- RC: Ropivacaine and Clonidine
- R: Ropivacaine

# **LIST OF TABLES**

Serial No.	<u>Table</u>	Page No.
1.	Comparison of study groups according to age	17
2.	Comparison of study groups according to body weight	18
3.	Comparison of study groups according to height	19
4.	Comparison of study groups according to time to sensory block onset	20
5.	Comparison of study groups according to number of dermatomes blocked	21
6.	Comparison of study groups according to time to first rescue analgesic	22
7.	Comparison of study groups according to number of patients requiring and not requiring rescue analgesic	24
8.	Comparison of study groups according to the quality of analgesia defined by Visual Analogue Scale(VAS)	25
9.	Comparison of study groups based on difference between heart rate of patients at the baseline(time since ESP block application), and heart rate at every five minutes till thirty minutes	27
10.	Comparison of study groups based on difference between systolic blood pressure of patients at the baseline(time since ESP block application),and systolic blood pressure at every five minutes till thirty minutes	28
11.	Comparison of study groups based on difference between diastolic blood pressure of patients at the baseline(time since ESP block application),and diastolic blood pressure at every five minutes till thirty minutes	29
12.	Comparison of study groups based on difference between mean arterial blood pressure of patients at the baseline(time since ESP block application), and mean arterial blood pressure at every five minutes till thirty minutes	30
13.	Comparison of study groups based on difference between oxygen saturation of patients at the baseline(time since ESP block application), and oxygen saturation at every five minutes till thirty minutes	31

14.	Comparison of study groups based on oxygen saturation every 5 minutes since ESP block application till 30mins	32
15.	Comparison of study groups based on difference between heart rate of patients at the baseline(pre-induction), and heart rate after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins	33
16.	Comparison of study groups based on difference between systolic blood pressure of patients at the baseline(pre-induction), and systolic blood pressure after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins	35
17.	Comparison of study groups based on difference between diastolic blood pressure of patients at the baseline(pre-induction), and diastolic blood pressure after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins	37
18.	Comparison of study groups based on difference between mean arterial blood pressure of patients at the baseline(pre-induction), and mean arterial blood pressure after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins	39

# **LIST OF FIGURES**

Serial No.	<u>Figure</u>	Page No.
1.	Anatomy of ESP block	2
2.	Ultrasound image of ESP block at T4 level	3
3.	CONSORT figure representing the enrolment and randomization of cases	16
4.	Comparison of mean age of patients (in years) in group RC(test) and R(control)	17
5.	Comparison of mean body weight of patients(kg) in groups RC(group A) and R(group B)	18
6.	Comparison of mean height of patients(in cm) in groups RC(group A) and R(group B)	19
7.	Comparison of time to sensory block onset(in minutes) in group RC and group R	20
8.	Comparison of number of dermatomes blocked in group RC and group R	21
9.	Comparison of median time to first rescue analgesic(in hours) in RC and R group	22
10.	Distribution of time to first rescue analgesic(in hours) in RC and R group shown by Kaplan-Meier survival curve	23
11.	Comparison of number of patients requiring and not requiring rescue analgesic in the RC group	24
12.	Comparison of number of patients requiring and not requiring rescue analgesic in the R group	24
13.	Comparison of mean resting VAS score for RC(test) and R(control) groups, indicated by open dots. The lines indicate error bars taken as +/-2SD	26
14.	Comparison of mean motor VAS score for RC(test) and R(control) groups, indicated by open dots. The lines indicate error bars taken as +/-2SD	26
15.	Comparison of median heart rate(per min) of patients of group RC(group 1) and group R(group 2)	27

16.	Comparison of median systolic blood pressure(SBP in mmHg) of patients of group RC(group 1) and group R(group 2)	28
17.	Comparison of median diastolic blood pressure(DBP in mmHg) of patients of group RC(group 1) and group R(group 2)	29
18.	Comparison of median MAP(mean arterial blood pressure in mmHg) of patients of group RC(group 1) and group R(group 2)	30
19.	Comparison of median SpO2(oxygen saturation in percent) of patients of group RC(group 1) and group R(group 2)	31
20.	Comparison of median heart rate(per min) of patients of group RC(group 1) and group R(group 2)	34
21.	Comparison of median systolic blood pressure(mmHg) of patients of group RC(group 1) and group R(group 2)	36
22.	Comparison of median diastolic blood pressure(mmHg) of patients of group RC(group 1) and group R(group 2)	38
23.	Comparison of median MAP(mmHg) of patients of group RC(group 1) and group R(group 2)	40

# **SUMMARY**

**Background:** Patients undergoing breast surgeries experience significant postoperative pain. Multimodal pain management protocols including the available pharmacological options have demonstrated improved pain control with less reliance on opioids. Use of regional anaesthesia (RA) techniques as a component of multimodal pain protocol can replace opioid-based analgesia. Recently, the erector spinae plane (ESP) block has been introduced in clinical practice as part of a multimodal pain strategy. The present study has been carried out to compare the effect of clonidine as an adjuvant to 0.5% Ropivacaine in ESP block for postoperative analgesia in breast surgeries.

**Objectives:** Our primary objective is to evaluate the analgesic efficacy of clonidine as an adjuvant in Erector Spinae Plane block in terms of duration of analgesia defined as time to first rescue analgesic (patient demand/VAS≥4) after breast surgeries. Onset of sensory block, number of dermatomes blocked, duration of sensory block, quality of analgesia (Visual Analogue Scale), total analgesic requirement in 24 hr postoperatively, and adverse effects/complications if any are noted.

Materials and methods: Patients aged between 18 - 65 years of age, belonging to ASA Physical Status I and/or II and undergoing unilateral modified radical mastectomy under general anaesthesia have been included in the study. They were allotted into one of the two groups- Group R (received inj 0.5% Ropivacaine in ESP block) and Group RC(received inj Clonidine 1μgm/kg with 0.5% Ropivacaine in ESP block). Unilateral ESP block under USG guidance was given on the side of surgery at T4 level, before induction of GA. Sensory level of block and onset of sensory block have been assessed. Vitals(HR,SBP,DBP,MAP,SPO2) were noted since ESP block application and thereafter every 5 minutes for thirty minutes. Intra-operative vitals were also noted till 90minutes. Postoperatively, patients was followed up for 24hours and VAS score were recorded every 30mins till 2 hours in PACU and then at 2,4,6,9,12,18 and 24<sup>th</sup> hour in the ward. Rescue analgesia IV diclofenac 1.5mg/kg was administered on patient demand or whenever VAS ≥ 4. At the end of the observation period, rescue analgesia required, side effect and patient satisfaction were recorded.

**Results:** Total eighty six patients were assessed for eligibility; fourteen patients were excluded in the beginning of the study as they were not meeting the inclusion criteria. Total

seventy two patients were enrolled for the study and randomised. The median time to first rescue analgesic was 18 hours in RC and 10 hours in R group. About 16% of patients of RC group and 33.3% of patients of R group demanded rescue analgesic in postoperative period. On comparison there was insignificant difference between groups in time to first rescue analgesic, p-value(0.40). Quality of analgesia defined by VAS score was also comparable between the study groups (p>0.05) at measured time points. Mean time to sensory block onset was 10.7 +/- 3.0 min in group RC and 10.3 +/- 0.9 min in group R (p 0.513). Mean number of dermatomes blocked was 4.4 +/- 1.0 in group RC and 4.5 +/- 0.5 in group R. Vital parameters (Heart Rate, Systolic Blood Pressure, Diastolic Blood Pressure, Mean Arterial Pressure) of patients since ESP block application, every 5mins till thirty minutes were comparable between the study groups(p>0.05) except oxygen saturation. Independent sample 't' test showed the difference in oxygen saturation to be statistically significant(p<0.05) at measured time points, the difference is clinically insignificant as the lowest spo2 being 98% which did not required intervention. Intraoperative vitals were studied between both the groups and were found comparable(p>0.05). No adverse effects were noted in any patient.

**Conclusion:** There is no effect of addition of Clonidine as an adjuvant to 0.5% Ropivacaine in ESP block on the time to first rescue analgesic, time to sensory block onset, the quality of analgesia, duration od sensory block, number of dermatomes blocked and total analgesic requirement in 24hours. No adverse effects/complications are noted.

#### INTRODUCTION

One of the most frequent surgical procedures performed in hospitals is breast surgery, and even relatively simple breast surgeries are associated with severe postoperative pain. The axillary component of the procedure is the main source of the severe initial postoperative pain that affects nearly 60% of breast surgery patients. With all their inherent drawbacks and adverse effects, opioid analgesics are nonetheless frequently utilised in current treatment techniques. Pain is a disagreeable feeling and emotional state brought on by real or potential tissue injury. According to how long it lasts, pain is typically categorised into two categories: acute pain and chronic pain. Acute pain is defined as pain that lasts less than one month and is related to surgical trauma, tissue injury, or disease states, whereas chronic pain is defined as pain that lasts more than three months. [1] There is little agreement on which elements of this multimodal therapy produce the best analgesia, despite the fact that current best practises emphasise a "multimodal approach" (i.e., employing a variety of medications and strategies to control pain after surgery). [2] Modified radical mastectomy (MRM), the most common surgical treatment for breast cancer, involves extensive skin removal from the entire breast with axillary evacuation. By reducing the need for general anaesthesia and opioids and regulating the surgical stress response, effective acute pain management protects immunological function. Poor postoperative pain management has detrimental physiological and psychological effects. [3] Regional blocks have been demonstrated to decrease postoperative pain scores, opioid needs, postoperative nausea and vomiting, pulmonary problems, and length of stay in the post-anaesthesia care unit for breast procedures. In relation to breast cancer surgery, there is also some evidence that regional anaesthesia techniques may help to reduce the use of opioids, which have been linked to immunosuppression and the progression of cancer, and may indirectly contribute to tumour inhibition by attenuating the surgical stress response. [4]

To completely anaesthetize patients during breast surgery, the pectoral nerves, intercostobrachial, intercostal (III, IV, V, and VI), and long thoracic nerve must be blocked. <sup>[3]</sup> The ESP block is an interfascial plane block that involves injecting local anaesthetics under ultrasound guidance deep into the erector spinae muscle, which is located next to the transverse processes of the thoracic vertebrae. Forero first described the ESP block in 2016 as a treatment for thoracic neuropathic pain. <sup>[5]</sup> As the erector spinae fascia stretches from the nuchal fascia cranially to the sacrum caudally, the medication spreads in a craniocaudal

manner over a number of levels. Without causing any systemic adverse effects, ESP block delivers both intraoperative and postoperative analgesia. <sup>[6]</sup>

The spinalis, longissimus thoracis, and iliocostalis muscles, which run vertically in the back, combine to form the erector spinae muscle (ESM). The local anaesthetic (LA) is placed near the tip of the transverse process of the vertebra, deeper than the ESM, to perform the ESP block. As a result, one dermatome has a median amount of LA in the cranio-caudal fascial plane for every 3.4 ml of injected volume. It also diffuses at various levels laterally to the intercostal space and anteriorly to the paravertebral and epidural areas. The spinal nerve's ventral and dorsal rami are affected by the LA. The anterior and lateral branches make up the ventral ramus (intercostal nerve). The entire anterolateral wall is sensory innervated via its terminal branches. The posterior wall receives sensory innervation from the dorsal ramus, which is split into two terminal branches. Additionally, the diffusion of LA to the paravertebral area via the costotransverse foramina and the intertransverse complex (levators, rotators, and intercostal muscles: intertransverse and costotransverse ligaments) results in visceral and somatic analgesia. [7]




Figure 1: Anatomy of ESP block




Figure 2:- Ultrasound image of ESP block at T4 level

Since sonoanatomy is easily visible and there are no nearby structures that could be injured by a needle, ESP block has a very minimal risk of problems. [8] A pneumothorax or hematoma is prevented by the transverse process, which serves as an anatomical barrier and prevents needle insertion into the pleura or blood vessels. Additionally, the distance between the needle and the vertebral canal means there is very little chance of spinal cord injury. A motor neuron and bladder function are preserved by an ESP block, allowing for early mobility. Since motor function is unaffected, spinal cord function can be immediately postoperatively evaluated neurologically. [4]

For analgesia during breast surgery, a number of nerve blocks, including paravertebral and pectoralis nerve blocks, have been researched. Both paravertebral blocks and pectoralis nerve blocks are well established in clinical practise, and both have been proven to be efficient for delivering analgesia following breast surgery. These methods do, however, have a number of shortcomings. For instance, the spread of local anaesthetic can obstruct the surgical field after completing the pectoralis nerve block. On contrary, paravertebral blocks can result in serious side effects like pneumothorax and intrathecal or epidural injections of local anaesthetic.<sup>[4]</sup>

An amide type local anaesthetic, ropivacaine is produced as the hydrochloride monohydrate of the S-enantiomer. [9] Ropivacaine 0.5% (5 pg/ml), with or without epinephrine, has been demonstrated in brachial plexus investigations to give an efficient, long-lasting sensory and motor block. According to reports, ropivacaine is more toxic than lidocaine but less hazardous than bupivacaine. [2] It blocks motor and sensory nerve fibres in distinct ways. The onset, duration, and intensity of motor block are frequently slower, shorter, and less intense than those of bupivacaine. Compared to Bupivacaine, it has less cardiotoxicity. [10]

There has always been a hunt for medications that can be used as adjuvants to the regional nerve block and prolong analgesia with fewer side effects. Because of their sedative, analgesic, perioperative sympatholytic, and cardiovascular stabilising effects with less need for anaesthesia, alpha-2 adrenergic receptor agonists have drawn attention. To prolong nerve blocks, alpha-2 agonists are used with local anaesthetics. <sup>[6]</sup> Through either local vasoconstriction and facilitation of C fibre blocking or straightforward diffusion along the nerve, their concomitant injection enhances the nerve block characteristic of local anaesthetics. <sup>[10]</sup>

A selective alpha-2 adrenergic agonist with partial alpha-1 agonist properties is clonidine hydrochloride. It is an imidazoline derivative that functions as an agonist on the central alpha-2 adrenergic system. 2-((2,6-dichlorophenyl) amino)-2-imidazoline hydrochloride is the chemical name for clonidine. Clonidine activates a pathway in the nucleus tractus solitarius (NTS) that suppresses excitatory cardiovascular neurons by acting as an alpha-adrenergic agonist. In the posterior hypothalamus and medulla, clonidine produces an alpha-antagonist action. The central nervous system's (CNS) final reaction is a decreased sympathetic outflow, which clinically results in a reduction in arterial blood pressure. [11]

In this study, we have planned to evaluate the effect of clonidine as an adjuvant to 0.5% ropivacaine in ESP block for breast surgeries. We have hypothesized that Clonidine as an adjuvant to 0.5% Ropivacaine in erector spinae plane block increases the duration of analgesia after unilateral modified radical mastectomy.

# **AIM**

To determine the efficacy of using clonidine as an adjuvant to 0.5%Ropivacaine in erector spinae plane block for post operative analgesia in breast surgeries.

# **OBJECTIVES**

#### Primary objective:

To evaluate the analgesic efficacy of clonidine as an adjuvant in Erector Spinae Plane block in terms of duration of analgesia defined as time to first rescue analgesic (patient demand/VAS≥4) after breast surgeries.

#### .

#### **Secondary objectives:**

- 1. Onset of sensory block(Block completion to grade 1 sensory block)
- 2. Number of dermatomes blocked
- 3. Duration of sensory block (ESP block to Onset of pain)
- 4. Quality of analgesia (Visual Analogue Scale)
- 5. Total analgesic requirement in 24 hr postoperatively
- 6. Adverse effects/complications if any

#### **HYPOTHESIS**

Clonidine as an adjuvant to 0.5%Ropivacaine in erector spinae plane block increases the duration of analgesia after unilateral modified radical mastectomy.

# **REVIEW OF LITERATURE**

Saritaswami *et al* conducted a RCT on 60 patients scheduled for upper limb surgeries under supraclavicular block by dividing them into two equal groups, Group C: (Bupivacaine 0.25% (35 cc) + clonidine 1  $\mu$ g/kg) and Group D: (Bupivacaine 0.25% (35 cc) + dexmedetomidine 1  $\mu$ g/kg). 80 patients posted for upper limb surgeries were assessed for suitability to enroll in the study. Seven patients declined to participate in the study. Five patients were excluded as they were posted for soft tissue surgeries of the upper limb. Eight patients were excluded as they were found to be on beta blockers, anticoagulation drugs and had uncontrolled diabetes mellitus. The remaining 60 patients fulfilling the inclusion criteria were randomly assigned to one of the two groups. Motor block was determined according to a modified Bromage scale for upper extremities on a 3-point scale:-

- Grade 0: Normal motor function with full flexion and extension of elbow, wrist and fingers
- Grade 1: Decreased motor strength with ability to move the fingers only
- Grade 2: Complete motor block with inability to move the fingers
- Sedation of patient was assessed by the Ramsay Sedation Score. At the end of the procedure, quality of operative conditions were assessed according to the following numeric scale:-
- Grade 4: (Excellent) No complaint from patient
- Grade 3: (Good) Minor complaint with no need for the supplemental analgesics
- Grade 2: (Moderate) Complaint that required supplemental analgesia
- Grade 1: (Unsuccessful) Patient given general anaesthesia

There was no protocol deviation pre-operatively and intraoperatively, except for one patient in group C who had to be given general anaesthesia for inadequate block. Both groups were comparable in terms of age, gender, weight and type of surgeries(P>0.001). The baseline hemodynamic parameters were comparable in both groups. Significantly lower pulse rate was observed at 60, 90 and 120 min, but not less than 60 beats/min, in Group D as compared with Group C (P<0.001). Systolic and diastolic blood pressure were found to be significantly lower than baseline from 30 to 120 min in Group D as compared with Group C (P<0.001). No treatment was required for this fall in blood pressure. The haemodynamic parameters were comparable at the end of 180 min. Onset of sensory block was faster in Group D than in Group C, while onset of motor block was faster in Group C than in Group D, but the difference was not statistically significant (P>0.001). Duration of sensory block was 227 min in Group C as compared with 413 min in Group D. Statistically significant longer duration of

sensory block was observed in Group D(P=0.001). The duration of motor block was 292min in Group C as compared with 472min in Group D. Again, duration of motor block was significantly longer in Group D(P=0.001). There was significant increase in duration of analgesia in Group D 456min as compared with Group C 289 min. The difference was statistically significant(P=0.001) In Group D, 80% of the patients achieved Grade IV quality of block as opposed to 40% in Group C (P<0.05). There were a total 17 patients in Group C with Grade 2 and 3 block and six patients in Group D who required sedation or sedation with analgesia. One patient in Group C required general anaesthesia as the block was inadequate. In this randomized, double-blinded trial, comparison was done between dexmedetomidine and clonidine ( $\alpha$  agonist) as an adjuvant to Bupivacaine in supraclavicular brachial plexus block, and it was found that there was a significantly increased duration of sensory and motor blockade in the dexmedetomidine group than in the clonidine group without any adverse effects.

Rosemary et al conducted a study on 48 ASA Physical Status 1 or 2 adult patients scheduled to undergo upper-extremity surgery (primarily hand surgery) under brachial plexus anesthesia. Patients were randomized to receive either ropivacaine 0.5% or bupivacaine 0.5%, according to a blind parallel group design. Each patient received a subclavian perivascular block according to the technique described by Winnie. After a paresthesia was elicited and negative aspiration was confirmed, 3 ml of the study drug was injected rapidly to produce a pressure paresthesia. The remaining 29 ml was then injected over a period of approximately 1 min, with negative aspiration for blood confirmed after each 5-ml increment. The intercostobrachial and medial brachial cutaneous nerves (T2) were then blocked separately by a subcutaneous injection of 3 ml of study drug over the axillary artery pulse. Sensory and motor function was evaluated before the block and at 2, 5, 10, 15, 20, 25, and 30 min after the block, then every 15 min until 5 h postblock, every 30 min until 12 h postblock, and every 60 min until complete recovery. Dermatomes located in the surgical field could not be tested during the operative procedure but were evaluated before and after the surgery. Sensory block was assessed in the C2 through T2 dermatomes and graded as follows:

0 = no loss of sensation to pinprick;

1 = analgesia (patient feels touch but not sharp);

2 = anesthesia (patient does not feel touch).

Motor block at the shoulder was assessed by asking the patient to elevate the arm while keeping the elbow straight (superior trunk function) and at the hand by grip strength (middle and inferior trunk function); it was graded as follows: 0 = no weakness, 1 = paresis, and 2 = paralysis. This study demonstrated that bupivacaine 0.5% and ropivacaine 0.5% were equally effective in providing brachial plexus anesthesia. Duration of anesthesia was also similar between agents, and both may be considered long-acting local anesthetics. So for subclavian perivascular brachial plexus block, ropivacaine 0.5% and bupivacaine 0.5% were similar in terms of onset of sensory and motor block, duration of sensory and motor block, incidence of analgesia, anesthesia, paresis and paralysis, and the need for supplementation.

**Bakr** *et al* conducted a study on 60 patients with ASA physical status I– II (18–60 years old and weighing 50–90 kg) scheduled for MRM were enrolled and randomly assigned into 2 groups (30 in each) to receive a preoperative US Pecs block with 30 mL of 0.25% bupivacaine only (group 1, bupivacaine group [GB]) or 30 mL of 0.25% bupivacaine plus 1 μg/ kg dexmedetomidine (group II, dexmedetomidine group [GD]). The patients were followed-up 48 hours postoperatively for vital signs (heart rate [HR], noninvasive blood pressure [NIBP], respiratory rate [RR], and oxygen saturation [Sao2]), visual analog scale (VAS) scores, time to first request of rescue analgesia, total morphine consumption, and side effects. Serum levels of cortisol and prolactin were assessed at baseline and at 1 and 24 hours postoperatively.

A significant reduction in the intraoperative HR, systolic blood pressure (SBP), and diastolic blood pressure (DBP) starting at 30 minutes until 120 minutes in the GD group compared to the GB group (P < 0.05) was observed. The VAS scores showed a statistically significant reduction in the GD group compared to the GB group, which started immediately up until 12 hours postoperatively (P < 0.05). There was a delayed time to first request of analgesia in the GD group 25hrs compared to the GB group 17 hrs (P = 0.029), and there was a significant decrease of the total amount of morphine consumption in the GD group (9 + 3.6 mg) compared to the GB group (12 + 3.6 mg) (P = 0.001). There was a significant reduction in the mean serum cortisol and prolactin levels at 1 and 24 hours postoperative in the GD patients compared to the GB patients (P < 0.05). The addition of 1  $\mu$ g/kg dexmedetomidine to an US-modified Pecs block has superior analgesia and more attenuation to stress hormone levels without serious side effects, compared to a regular Pecs block in patients who underwent MRM.

Chandni et al conducted a RCT on 64 adult female patients with ASA PS 1 and 2 who were scheduled for unilateral modified radical mastectomy with first group under USG guided ESP block(with 20cc 0.2% Ropivacaine) and the second group under USG guided PECS II block (25 cc 0.2% ropivacaine). Various parameters observed included sensory blockade, duration of analgesia and any adverse effects. The blocks were performed under aseptic precautions 30 minutes before surgery with a 22 gauge echogenic needle and linear array probe. The patients were observed for 30 minutes after performing the block. The anaesthesiologist who was blinded to the technique of block assessed the sensory level of block with pin-prick sensation in each side from T1 to T8. The total number of dermatomes that had less pain to pin prick compared with opposite side were noted. If the pin-prick sensation did not decrease in any segment up to 30 minutes, it was considered as a block failure and patients were excluded from the analysis. The patient's ECG and SpO2 were monitored continuously, and heart rate (HR) and NIBP were recorded at baseline, after performing the block, and every 5 minutes for 30 minutes. Any block-related complications, such as hypotension, vascular puncture, pneumothorax were looked for. General anaesthesia was administered in a standardised manner. Postoperatively patient-controlled analgesia pump was connected to the patients. Postoperative pain was assessed using a numerical rating scale (NRS, 0–10; 0 = no pain and 10 = worst imaginable pain). No basal infusion was given and only bolus doses of 1- 2 mg morphine with a 10 minute lock out interval was allowed. The total analgesic consumption in 24 hours was taken as the primary outcome measure. The secondary outcome measures included duration of analgesia (time to first rescue analgesia after administration of block), the level of sensory blockade as assessed preoperatively and the postoperative pain scores. Adverse effects such as hypotension, respiratory depression were looked for and treatment planned (fluid bolus 10 ml/kg and oxygen supplementation with simple face mask at 5L/min). The quantitative variables were compared using the unpaired student t-test. The qualitative variables were compared using the Chi-square test. P < 0.05 was considered statistically significant. This prospective study shows that PECS block performed in patients scheduled for MRM results in better pain control and less postoperative morphine consumption in the first 24 hours. Hence it is a superior block than ESP in patients scheduled for MRM surgeries.

**Kulhari.S** *et al* conducted a study on forty adult female patients undergoing radical mastectomy who were randomly allocated into two groups. Group 1 patients received a TPVB with ropivacaine 0.5%, 25 ml, whereas Group 2 patents received a PecS II block using same volume of ropivacaine 0.5% before induction of anaesthesia. Patient-controlled

morphine analgesia was used for postoperative pain relief. The duration of analgesia was significantly prolonged in patients receiving the PecS II block compared with TPVB [mean (sd), 294.5 (52.76) vs 197.5 (31.35) min in the PecS II and TPVB group, respectively; P<0.0001]. The 24 h morphine consumption was also less in the PecS II block group [mean (sd), 3.90 (0.79) vs 5.30 (0.98) mg in PecS II and TPVB group, respectively; P<0.0001]. Postoperative pain scores were lower in the PecS II group compared with the TVPB group in the initial 2 h after surgery [median (IQR), 2 (2-2.5) vs 4 (3-4) in the Pecs II and TPVB group, respectively; P<0.0001]. Seventeen patients in the PecS II block group had T2 dermatomal spread compared with four patients in the TPVB group (P<0.001). No block-related complication was recorded. It was found that the PecS II block provided superior postoperative analgesia than the TPVB in patients undergoing modified radical mastectomy without causing any adverse effect.

**Kalyani** *et al* conducted a RCT on 60 adult patients posted for upper limb surgeries under supraclavicular block By dividing them into two groups:-

Group I: 30 ml 0.75% ropivacaine +1 ml normal saline

Group II: 30 ml 0.75% ropivacaine +1 mcg/kg clonidine diluted to 1 ml with normal saline.

Dexmedetomidine when added to local anaesthetic in supraclavicular brachial plexus block enhanced the duration of sensory and motor block and also the duration of analgesia. The time for rescue analgesia was prolonged in patients receiving dexmedetomidine. It also enhanced the quality of block as compared with clonidine. Following operation, all patients were observed in postanesthesia care unit and received rescue analgesic (aqueous diclofenac 75 mg slow IV) on demand. The time from the end of anesthetic injection in the operated hand until the first request for postoperative rescue analgesic was recorded in each patient. The duration of sensory block was defined as the time interval between injection and complete recovery of sensation. The duration of motor block was defined as the time interval between completion of injection and complete recovery of motor power. The statistical analysis was performed using two-independent sample t-test and  $P \le 0.05$  was statistically significant. There was no statistically significant difference in the demographic profile and the baseline values of hemodynamic variables between the two groups. One patient in the control group had block failure and was given general anesthesia. He was excluded from further statistical analysis involving block characteristics and hemodynamic changes after the block. Significantly lower pulse rate was observed from 60 min to 180 min in the clonidine group,

but was not clinically significant and did not need any intervention Mean arterial pressure dropped at 30-min and remained so until 150-min in the clonidine group. No treatment was required for this fall in blood pressure. The hemodynamic parameters were comparable by 180-min. The onset of sensory block and motor block was significantly faster in clonidine group than control group. The duration of sensory block was  $703.83 \pm 42.90$  min in clonidine group when compared to  $556.38 \pm 37.96$  min in control group. The duration of motor block was  $621.67 \pm 46.76$  min in clonidine group and  $500.86 \pm 44.58$  min in control group [Figure 4]. Both were significantly prolonged in clonidine group (P < 0.001). The mean time for rescue analgesia in control group was  $613.10 \pm 51.797$  min and in clonidine group was  $878.33 \pm 89.955$  min. Significantly prolonged duration for rescue analgesia was observed in clonidine group (P < 0.001)Ropivacaine 0.75% used in brachial plexus block is well tolerated and provides effective surgical anesthesia as well as relief of postoperative pain. Clonidine as an adjuvant to ropivacaine significantly enhances the quality of supraclavicular brachial plexus block by faster onset, prolonged duration of sensory and motor block and improved postoperative analgesia, without associated adverse effects.

Zhixin et al conducted a RCT on 90 adult patients aged 20-65 years, had an American Society of Anesthesiologists physical status (ASA) of I or II, who were posted for VATLS(video assisted thoracoscopic lobectomy surgery) under USG guided ESP block.He divided them into three groups, first group was given Ropivacaine alone, second group was given Dexamethasone as an adjuvant to Ropivacaine and the third group was given Dexmedetomidine as an adjuvant to Ropivacaine. After obtaining a written informed consent, all patients were taught to evaluate their own pain by using a 10-cm visual analog pain scale (0= no pain, 10= maximum pain imaginable) and how to use the patient controlled analgesia (PCA) device at the preoperative visit. All patients were then randomized to one of three groups using computer generated random numbers and a 1:1:1 allocation ratio. Patients were placed in a standard lateral position to apply ESPB before inducing anesthesia. An assistant, who was neither involved in the study nor was participating in the perioperative period or the postoperative follow-up, prepared study drugs. Groups received 0.5% ropivacaine 30 mL (R) or 0.5% ropivacaine 30 mL with 10 mg dexamethasone (RS) or 0.5% ropivacaine 30 mL with 1 μg/kg dexmedetomidine (RM), deep to the erector spinae muscle adjacent to transverse processes.lowing standardized monitoring, which included noninvasive blood pressure (NIBP), electrocardiogram (EKG), and pulse oximetry (PO). They were performed at the T5 level of the spine using an in-plane approach. Sensory block of the 5th intercostal space in the

midaxillary line was assessed by bilaterally using cold perception for 30 min after applying the nerve block. The patient was excluded from the study if sensory blockade was unsuccessful. Sufentanil (0.1–0.2 µg/kg) and flurbiprofen (50 mg) were intravenously administered, followed by patientcontrolled analgesia (PCA) pump use before the end of the surgery. PCA capacity was 250 mL and contained 7.5 µg/kg sufentanil and 250 mg flurbiprofen. The infusion rate was maintained at 2 mL/h, and the patient-controlled bolus was 2 mL with a lockout interval of 15 min. They were trained to press for an additional bolus if a 10 cm visual analog scale (VAS) for postoperative pain exceeded 3, and first time request for pressing PCA was recorded. In the situation when the VAS score remained ≥4 after using the PCA, the patients received tramadol 100 mg intramuscularly injectionas rescue analgesic. He performed a cold perception test in comparison with the contralateral intercostal area. Duration of sensory block was the time period from establishing the block to 100% cold perception in all sensory areas (100%= no difference to the contra-lateral side; 0% = complete sensory loss). The primary end point was postoperative PCA use during the first 72 h. Secondary outcomes included: (I) consumption of sufentanil, remifentanil, and propofol during anesthesia; (II) a 10 cm VAS for pain (0–10; 0, no pain; 10, worst imaginable pain) and changes in the VAS score at various time points: wake up in PACU and 2, 4, 6, 8, 12, 24, 48, 72 h after surgery; (III) optimum duration of sensory block; (IV) initial request for using PCA; and (V) incidence of postoperative nausea and vomiting(PONV) and rescue analgesia in the ward and the hospital stay after surgery. There was no significant difference in intraoperative characteristics among groups, which includes duration of surgery and the consumption of sufentanil, remifentanil, and propofol. Group RM demonstrated longer durations of sensory block and delayed first time of using the PCA machine than that in group R and group RS. Group RM demonstrated reduced total PCA machine use, the requirement for rescue analgesia, and postoperative hospital stay than group R and RS. There was no significant difference in the PONV occurrence rate among the groups. Dexmedetomidine, which was used as an adjuvant of ESPB with ropivacaine, prolonged sensory block duration, provided effective acute pain control after surgery, and reduced the need for rescue analgesia. It also shortened postoperative hospital stay for patients undergoing VATLS. However, dexamethasone had no clinically relevant effect on the duration of sensory block and postoperative pain control by ropivacaine at ESPB.

# MATERIALS AND METHODS

**STUDY SETTING:** This prospective, randomized study was carried out in department of Anaesthesia and Critical Care at All India Institute of Medical Sciences (AIIMS), Jodhpur.

**STUDY DESIGN:** Prospective, interventional, comparative trial.

**INCLUSION CRITERIA:** Patients aged between 18 - 65 years of age, belonging to ASA Physical Status I and/or II and undergoing unilateral modified radical mastectomy was included in the study.

**EXCLUSION CRITERIA:** Patients refusal, pregnant patients, patients with baseline cognitive deficits, coagulopathy, liver and renal dysfunction, and known allergy to amide local anaesthetics or opioid was excluded.

**DURATION OF STUDY:** The study was carried out in 72 patients. Enrollment of patients started in September 2021 and ended in August 2022. Approval was taken from the Institutional Ethics Committee (IEC Reg No.- AIIMS/IEC/2021/3327, dated 12/03/2021) and the study was registered with Clinical Trial Registry – India (CTRI Reg. No. CTRI/2021/09/036792 dated 01/09/2021).

On the day before surgery, enrolled patients were acquainted with visual analogue scale. Based on the computer-generated random numbers they were alotted into one of the two groups- Group R (will be receiving inj 0.5% Ropivacaine in ESP block) and Group RC(will be receiving inj Clonidine 1µgm/kg with 0.5% Ropivacaine in ESP block). The group allocation numbers were concealed in sealed opaque envelopes that were opened only after shifting the patient to preoperative holding area by a person not involved in the study. He also prepared and handed over the drug to be administered for the block during the procedure. The monitors attached included non-invasive blood pressure (NIBP), electrocardiography (ECG), and peripheral oxygen saturation (SPO2). An 18 G I.V cannula was secured in the opposite hand and fluid was started.

Patients in both groups received ESP block on the side of surgery. The blocks were performed under aseptic precautions 30 minutes before surgery with a 22 gauge echogenic needle using ultrasound machine and linear array probe (38 mm, 7-12 MHz frequency). Erector spinae

plane block was given with the patient in the sitting position. To give the block, the high frequency linear probe was placed in a transverse orientation to visualize right lateral tip of T4 transverse process. After identifying the three muscles namely trapezius, rhomboid major, and erector spinae, superficial to the hyperechoic transverse process, the probe was turned 90 degree longitudinally. After infiltrating 2 ml of 2% lignocaine, the block needle was inserted in a cephalo caudad direction to contact the transverse process. The correct placement was indicated by linear fluid spread that lifted the erector spinae muscle off the underlying transverse processes and intercostal muscles. After hydrodissection with saline solution, 20ml of LA solution containing 0.5% ropivacaine with or without clonidine (1microgram per kg), as per the group allocation and prepared by person uninvolved in the study was injected.

The patients were observed for 30 minutes after performing the block. The sensory level of block was assessed with pin-prick sensation from T1 to T8 and compared from the other side.

#### Sensory block grading:

- 0 -> no loss of sensation to pinprick
- 1 -> Analgesia(patient feels touch but not pin prick)
- 2->Anaesthesia(patient does not feel touch)

The total number of dermatomes that has less pain to pin prick compared with opposite side was noted. Onset of sensory block was defined as the time starting after drug administration to sensory grade 1. The patient's ECG and SpO2 was monitored continuously, and heart rate (HR) and NIBP was recorded at baseline, after performing the block, and every 5 minutes for 30 minutes. Any block-related complications, like hypotension, bradycardia, hematoma, pneumothorax, sedation, nausea, vomitting, dry mouth were recorded.

General anaesthesia was then given in both groups.Intraoperative monitoring of HR ,BP(systolic diastolic mean) were recorded at baseline,induction,after securing airway,at skin incision,then every 15 mins till end of surgery.Intraoperaively,additional dose of 1 microgram per kg fentanyl was given when HR or BP increased to more than 20% of baseline parameters.Injection paracetamol 1gm iv was given on surgical closure and 6hourly in the postoperative period. After completion of surgery,patient was shifted to PACU,where baseline VAS score were recorded and intervention was started. In both the groups,VAS was recorded every 30mins till 2 hours in PACU and then at 2,4,6,9,12,18 and 24<sup>th</sup> hour in the ward. Rescue analgesia IV diclofenac 1.5mg/kg was administered on patient demand or

whenever  $VAS \ge 4$  was recorded. At the end of the observation period, rescue analgesia required, side effect and patient satisfaction were recorded.

#### **SAMPLE SIZE CALCULATION**

The sample size was determined using data from a formerly published study done by Kulhari.S *et al* on forty adult female patients underging radical masectomy and found that the duration of analgesia was significantly prologned in patients receiving PecS II block compared with TPVB. They reported the duration of analgesia to be (294.5 +/- 52.76) min in patient receiving PecS II block. To detect a 15% increase in analgesia duration following the intervention, we had estimated a sample size of 66 (33 patients per group) at 95% CI, 90% power and 10% contingency. Considering block failure rate to be maximum of 10%, the final sample size was determined to be 72(36 patients per group).


#### **STATISTICAL ANALYSIS**

The data normality is checked by using Shapiro-Wilk test. The quantitative data are presented as the mean  $\pm$  SD as well as Median,Q1 and Q3. The comparison of the variables that are quantitative in nature are analyzed using Independent t test and Mann-Whitney U test(for two groups). The comparison of the variables that are ordinal in nature are analyzed using Fischer's exact test(for two groups). For statistical significance, p value of less than 0.05 is considered statistically significant.

The data entry is done in the Microsoft EXCEL spreadsheet and the final analysis is done with the use of Statistical Package for Social Sciences (SPSS) software, IBM manufacturer, Chicago, USA, version 21.0.

# **RESULTS**

In this study total eighty six patients were assessed for eligibility; fourteen patients were excluded in the beginning of the study as they were not meeting the inclusion criteria. Total seventy two patients were enrolled for the study and randomised. They were allocated to intervention groups RC and R, analysed and the results were computed.




<u>Figure 3</u>: CONSORT figure representing the enrolment and randomization of cases

**Table 1:-** Comparison of study groups according to age

Parameter	Group RC	Group R	p-value
Age(years)	54.7 +/- 12.6	52 +/- 13.0	0.410

The above table shows the age of patients of the RC (ropivacaine+clonidine) and R(ropivacaine) groups, calculated as Mean +/- SD. The difference between both the groups is insignificant, statistically for the parameter age of patients(p>0.05). Independent sample 't' test is used to compare the age of patients between the study groups.



**Figure 4:** Comparison of mean age of patients (in years) in group RC(test) and R(control).

Table 2:- Comparison of study groups according to body weight

Body Weight (kg)	Group RC	Group R	p-value
Mean±SD	61.89 ± 12.22	59.94 ±10.76	0.4937

The above table shows the body weight of patients of the RC (ropivacaine+clonidine) and R(ropivacaine) groups, calculated as Mean +/- SD. The difference between both the groups is insignificant, statistically(p>0.05). Unpaired student 't' test is used to compare the age of patients between the study groups.





Figure 5: Comparison of mean body weight of patients (kg) in groups RC( group A) and R (group B).

**Table 3:-** Comparison of study groups according to height

Height (cm)	Group RC	Group R	p-Value
Mean±SD	$152.14 \pm 4.78$	$152.68 \pm 5.64$	0.67

The above table shows the body weight of patients of the RC (ropivacaine+clonidine) and R(ropivacaine) groups, calculated as Mean +/- SD. The difference between both the groups is insignificant, statistically(p>0.05). Unpaired student 't' test is used to compare the age of patients between the study groups.



**Figure 6:** Comparison of mean height of patients(in cm) in groups RC(group A) and R(group B).

Table 4:- Comparison of study groups according to time to sensory block onset

Parameter	Group RC	Group R	p-value
Time to sensory block onset(minutes)	10.7 +/- 3.0	10.3 +/- 0.9	0.513

The above table shows the time to sensory block onset of the RC (ropivacaine+clonidine) and R(ropivacaine) groups, calculated as Mean +/- SD. The difference between both the groups is insignificant, statistically for the parameter time to sensory block onset(p>0.05). Independent sample 't' test is used to compare the mean time to sensory block onset between the study groups.




Figure 7: Comparison of time to sensory block onset(in minutes) in group RC and group R.

Table 5:- Comparison of study groups according to number of dermatomes blocked

Parameter	Group RC	Group R	p-value
Number of dermatomes blocked	4.4 +/- 1.0	4.5 +/- 0.5	0.606

The above table shows the number of dermatomes blocked in the RC (ropivacaine+clonidine) and R(ropivacaine) groups, calculated as Mean +/- SD. The difference between both the groups is insignificant, statistically for the parameter number of dermatomes blocked(p>0.05). Independent sample 't' test is used to compare the mean number of dermatomes blocked between the study groups.




Figure 8: Comparison of number of dermatomes blocked in group RC and group R.

<u>Table 6:-</u> Comparison of study groups according to time to first rescue analgesic

# A) Calculation according to Mann-Whitney U test

Group	Median of time to		IQR	p-value
	analgesic(hrs)	Q1	Q3	P (Manual
RC	18.00	13.25	21.25	
R	10.50	6.25	21.75	0.400

The above table shows the median time to first rescue analgesic(hours), Q1, and Q3 in the RC (ropivacaine+clonidine) and R(ropivacaine) groups. The median time to first rescue analgesic is 18 hours in RC and 10 hours in R group. Mann-Whitney U test is used to calculate it. There is no significant difference on time to first rescue analgesic between both the groups(p>0.05).





Figure 9:- Comparison of median time to first rescue analgesic(in hours) in RC and R group.

#### B) Calculation according to Chi-square test

Group	Median of time to		IQR	p-value
	analgesic(hrs)	Q1	Q3	-
RC	16.000	9.999	22.001	
R	9.000	2.210	15.790	0.925

The above table shows the median time to first rescue analgesic(hours), Q1, and Q3 in the RC (ropivacaine+clonidine) and R(ropivacaine) groups. The median time to first rescue analgesic is 16 hours in RC and 9 hours in R group. Chi-square test is used to calculate it. There is no significant difference on time to first rescue analgesic between both the groups(p>0.05).




<u>Figure 10:-</u> Distribution of time to first rescue analgesic(in hours) in RC and R group shown by Kaplan-Meier survival curve.


<u>Table 7:-</u> Comparison of study groups according to number of patients requiring and not requiring rescue analgesic

Parameters	Group RC	Group R	p-value
No of patients requiring rescue analgesic	6(16%)	12(33.3%)	0.086
No of patients not requiring rescue analgesic	30(84%)	24(66.6%)	0.000

The above table shows the number of patients requiring and not requiring rescue analysesic calculated as percentage. Six patients in RC group and twelve patients in R group requires rescue analysesic. The difference between both the groups is statistically insignificant (p>0.05). P-value is calculated using Chi-square test.



<u>Figure 11:-</u> Comparison of number of patients requiring and not requiring rescue analgesic in the RC group.




<u>Figure 12:-</u> Comparison of number of patients requiring and not requiring rescue analgesic in the R group.

<u>Table 8:-</u> Comparison of study groups according to the quality of analgesia defined by Visual Analogue Scale (VAS)


Parameters	Group	Mean	Std. Deviation	p-value
VAS D 20Min	RC	2.2778	1.00317	0.244
VAS_R_30Min	R	2.5429	0.81684	
VAC D COMin	RC	2.2500	0.96732	0.414
VAS_R_60Min	R	2.5278	0.90982	
VAC D OOM:	RC	2.1667	1.08233	0.002
VAS_R_90Min	R	2.9167	0.90633	
VAC D 2Hr	RC	1.9722	0.65405	0.894
VAS_R_2Hr	R	2.0833	0.60356	
VAC D /II.	RC	2.1111	0.57459	0.355
VAS_R_4Hr	R	2.2222	0.72155	
VAC D GIL	RC	2.1389	0.96074	0.463
VAS_R_6Hr	R	2.0833	0.80623	
VAC D OIL	RC	2.0278	0.44633	0.168
VAS_R_9Hr	R	2.2778	0.97427	
VAC D 1011.	RC	1.9722	0.55990	0.675
VAS_R_12Hr	R	2.0278	0.60880	
VAC D 10II.	RC	2.0833	0.76997	0.817
VAS_R_18Hr	R	2.1389	0.79831	
VAC D 24Hr	RC	2.2778	0.94449	0.790
VAS_R_24Hr	R	2.2500	1.15573	
VAC M 20Min	RC	2.7778	0.59094	0.323
VAS_M_30Min	R	3.1111	0.70823	
VAS M 60Min	RC	2.9722	0.77408	0.053
VAS_M_60Min	R	3.3611	0.89929	
VAS M OOMin	RC	3.1111	1.06309	0.435
VAS_M_90Min	R	3.7500	0.96732	
VAS M 2Hr	RC	2.9722	0.65405	0.630
VAS_IVI_ZIII	R	3.0556	0.58282	
VAS_M_4Hr	RC	3.0833	0.55420	0.131
VA9_I/I_4UI	R	3.2500	0.73193	
VAS M 6Hr	RC	3.1111	0.94952	0.595
VAP_IM_OHI	R	3.1111	0.78478	
VAS_M_9Hr	RC	3.0278	0.44633	0.391
VAS_IVI_3111	R	3.1944	1.06421	
VAS_M_12Hr	RC	3.0556	0.47476	0.749
VAS_IVI_12ПI	R	3.0000	0.67612	
VAS M 10H.	RC	3.1667	0.91026	0.233
VAS_M_18Hr	R	3.1389	0.68255	
VAS M 24Hr	RC	3.2222	0.92924	0.420
VAS_IVI_24ПI	R	3.2222	1.22150	

The above table shows the resting(R) and motor(M) VAS scores of the RC and R groups at 30minutes, 1hour, 90minutes, 2hours, 4hours, 6hours, 9hours, 12hours, 18hours and 24<sup>th</sup>hour

of the postoperative period, calculated as Mean +/- SD. The difference between both the groups is found to be statistically significant for resting VAS score at 90min(p<0.05), but is insignificant for VAS score at other time points. Independent sample 't' test is used to compare the mean VAS score between the study groups. Although VAS(resting) at 90 minutes is significant statistically, but is insignificant clinically(Mean VAS at 90mins being 2.1 and 2.9 for RC and R groups respectively), as they are beyond the criteria to administer rescue analgesic(VAS greater or equal to 4).



**Figure 13:-** Comparison of mean resting VAS score for RC(test) and R(control) groups, indicated by open dots. The lines indicate error bars taken as +/-2SD.




**Figure 14:-** Comparison of mean motor VAS score for RC(test) and R(control) groups, indicated by open dots. The lines indicate error bars taken as +/-2SD.

<u>Table 9:-</u> Comparison of study groups based on difference between heart rate of patients at the baseline (time since ESP block application), and heart rate at every five minutes till thirty minutes

	Group						
Parameters	RC						
	Median	Q1	Q3	Median	Q1	Q3	p-value
Time to block (baseline-5mins)	0.0	-1.0	0.0	0.0	0.0	0.0	0.224
HR(per min)	0.0	-1.0	0.0	0.0	0.0	0.0	0.224
Time to block (baseline-10mins)	0.0	0.0	0.0	0.0	0.0	0.0	0.688
HR(per min)	0.0		0.0	0.0			0.000
Time to block (baseline-15mins)	0.0	-1.0	0.0	0.0	0.0	0.0	0.342
HR(per min)	0.0	-1.0	1.0 0.0	0.0	0.0	0.0	0.342
Time to block (baseline-20mins)	-2.0	-3.0	3.0 0.0	-2.0	-3.0	-1.0	0.632
HR(per min)	-2.0	-3.0		-2.0	-3.0		0.032
Time to block (baseline-25mins)	0.0	0.0 0.0	0.0 0.0		0.0	0.723	
HR(per min)	0.0	0.0	0.0	0.0	0.0	0.0	0.723
Time to block (baseline-30mins)	0.0	0.0	0.0	0.0	0.0	0.0	0.586
HR(per min)	0.0	0.0	0.0	0.0	0.0	0.0	0.380

The above table shows the difference between heart rate of patients of group RC and R, at the baseline(time since ESP block application), and heart rate at every five minutes till thirty minutes, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above. Mann-Whitney U test and Independent sample 't' test is used to compare them. The differences have been found to be statistically insignificant(p>0.05).




**Figure 15:-** Comparison of median heart rate(per min) of patients of group RC(group 1) and group R(group 2).

<u>Table 10:-</u> Comparison of study groups based on difference between systolic blood pressure of patients at the baseline (time since ESP block application), and systolic blood pressure at every five minutes till thirty minutes

	Group						
Parameters	RC			R			
	Median	Q1	Q3	Median	Q1	Q3	p-value
Time to block (baseline-5mins)	0.0	0.0	0.0	0.0	0.0	0.0	0.458
SBP(mmHg)	0.0	0.0	0.0	0.0	0.0	0.0	0.436
Time to block (baseline-10mins)	0.0	0.0 2.0	00 20	0.0	0.0	0.0	0.317
SBP(mmHg)	0.0		2.0	0.0			0.317
Time to block (baseline-15mins)	0.0	0.0	0.0	0.0	0.0	0.0	0.251
SBP(mmHg)	0.0	0.0	0.0	0.0	0.0	0.0	0.231
Time to block (baseline-20mins)	0.0	0.0	2.0	0.0	-1.0	0.0	0.123
SBP(mmHg)	0.0	0.0	2.0	0.0	-1.0	0.0	0.123
Time to block (baseline-25mins)	0.0	0.0	2.0	0.0	0.0	0.0	0.114
SBP(mmHg)	0.0	0.0	2.0	0.0	0.0	0.0	0.114
Time to block (baseline-30mins)	0.0	0.0	0.0	0.0	0.0	0.0	0.249
SBP(mmHg)	0.0	0.0	0.0   0.0	0.0	0.0	0.0	0.243

The above table shows the difference between systolic blood pressure of patients of group RC and R, at the baseline(time since ESP block application), and systolic blood pressure at every five minutes till thirty minutes, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above.Mann-Whitney U test and Independent sample 't' test is used to compare them.The differences have been found to be statistically insignificant (p>0.05).




**Figure 16:-** Comparison of median systolic blood pressure(SBP in mmHg) of patients of group RC(group 1) and group R(group 2).

<u>Table11:-</u> Comparison of study groups based on difference between diastolic blood pressure of patients at the baseline(time since ESP block application), and diastolic blood pressure at every five minutes till thirty minutes

	Group						
Parameters	RC			R			
	Median	Q1	Q3	Median	Q1	Q3	p-value
Time to block (baseline-5mins) DBP(mmHg)	0.0	0.0	0.3	0.0	0.0	0.0	0.368
Time to block (baseline-10mins) DBP(mmHg)	0.0	0.0	1.0	0.0	0.0	0.0	0.237
Time to block (baseline-15mins) DBP(mmHg)	0.0	0.1	0.0	0.0	0.0	0.0	0.161
Time to block (baseline-20mins) DBP(mmHg)	0.0	0.0	3.0	0.0	-1.0	0.0	0.223
Time to block (baseline-25mins) DBP(mmHg)	0.0	0.1	2.0	0.0	0.0	0.0	0.214
Time to block (baseline-30mins) DBP(mmHg)	0.0	0.1	0.0	0.0	0.0	0.0	0.169

The above table shows the difference between diastolic blood pressure of patients of group RC and R, at the baseline(time since ESP block application), and diastolic blood pressure at every five minutes till thirty minutes, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above.Mann-Whitney U test and Independent sample 't' test is used to compare them.The differences have been found to be statistically insignificant(p>0.05).




**Figure 17:-** Comparison of median diastolic blood pressure(DBP in mmHg) of patients of group RC(group 1) and group R(group 2).

<u>Table 12:-</u> Comparison of study groups based on difference between mean arterial blood pressure of patients at the baseline(time since ESP block application), and mean arterial blood pressure at every five minutes till thirty minutes

	Group						
Parameters	RC			R			
	Median	Q1	Q3	Median	Q1	Q3	p-value
Time to block (baseline-5mins)	0.0	0.0	0.3	0.0	0.0	0.0	0.823
MAP(mmHg)	0.0	0.0	0.5	0.0	0.0	0.0	0.623
Time to block (baseline-10mins)	0.0	0.0	22.3	0.0	0.0	0.0	0.467
MAP(mmHg)	0.0	0.0		0.0	0.0		0.407
Time to block (baseline-15mins)	0.0	0.0	21.3	0.0	0.0	0.0	0.342
MAP(mmHg)	0.0	0.0	21.3	0.0	0.0	0.0	0.342
Time to block (baseline-20mins)	0.0	-0.3	22.3	0.0	0.0	0.3	0.617
MAP(mmHg)	0.0	-0.3	22.3	2.3 0.0	0.0	0.5	0.617
Time to block (baseline-25mins)	0.0	0.2	0.0	0.0	0.0	0.0	0.244
MAP(mmHg)	0.0	-0.3	-0.3   0.0	.0   0.0	0.0	0.0	0.244
Time to block (baseline-30mins)	0.0	-0.3	0.0	0.0	0.0	0.0	0.184
MAP(mmHg)	0.0	-0.3	0.0	0.0	0.0	0.0	0.184

The above table shows the difference between mean arterial blood pressure of patients of group RC and R, at the baseline(time since ESP block application), and diastolic blood pressure at every five minutes till thirty minutes, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above.Mann-Whitney U test and Independent sample 't' test is used to compare them. The differences have been found to be statistically insignificant(p>0.05).




**Figure 18:-** Comparison of median MAP(mean arterial blood pressure in mmHg) of patients of group RC(group 1) and group R(group 2).

<u>Table 13:-</u> Comparison of study groups based on difference between oxygen saturation of patients at the baseline(time since ESP block application), and oxygen saturation at every five minutes till thirty minutes

	Group						
Parameters	RC			R			
	Median	Q1	Q3	Median	Q1	Q3	p-value
Time to block (baseline-5mins)	0.0	0.0	0.0	0.0	0.0	2.0	0.001
SpO2(percent)	0.0	0.0	0.0	0.0	0.0	2.0	0.001
Time to block (baseline-10mins)	0.0	0.0	0.0	0.0	0.0	2.0	0.007
SpO2(percent)	0.0	0.0		0.0			0.007
Time to block (baseline-15mins)	0.0	0.0	0.0	0.0	0.0	2.0	0.001
SpO2(percent)	0.0	0.0	0.0	0.0	0.0	2.0	0.001
Time to block (baseline-20mins)	0.0	0.0	0.0	0.0	0.0	2.0	0.001
SpO2(percent)	0.0	0.0	0.0		0.0		
Time to block (baseline-25mins)	0.0	0.0	0.0	0.0	0.0	2.0	0.001
SpO2(percent)	0.0	0.0	0.0	0.0	0.0	2.0	0.001
Time to block (baseline-30mins)	0.0	0.0	0.0	0.0	0.0	2.0	0.001
SpO2(percent)	0.0	0.0	0.0	0.0	0.0	2.0	0.001

The above table shows the difference between oxygen saturation of patients of group RC and R, at the baseline(time since ESP block application), and diastolic blood pressure at every five minutes till thirty minutes, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above.Mann-Whitney U test and Independent sample 't' test is used to compare them.The differences have been found to be statistically significant(p>0.05).



**Figure 19:-** Comparison of median SpO2(oxygen saturation in percent) of patients of group RC(group 1) and group R(group 2).

<u>Table 14:-</u> Comparison of study groups based on oxygen saturation every 5 minutes since ESP block application till 30mins


Parameters	Group RC	Group R	p-value
Time to block - baseline spo2	99.5 +/- 1.1	98.3 +/- 2.0	0.002
Time to block - 5 min spo2	99.5 +/- 1.1	98.0 +/- 1.6	<0.001
Time to block -10 min spo2	99.7 +/- 4.1	99.2 +/- 3.9	0.016
Time to block -15 min spo2	99.7 +/- 4.1	99.1 +/- 3.9	0.015
Time to block -20 min spo2	99.7 +/- 4.1	99.1 +/- 3.9	0.015
Time to block - 25 min spo2	99.5 +/- 1.1	98.0 +/- 1.6	<0.001
Time to block - 30 min spo2	99.5 +/- 1.1	98.0 +/- 1.6	<0.001

The above table shows the mean oxygen saturation of patients at baseline and for every 5mins thereafter ESP block application ,till 30mins,for RC and R groups, calculated as Mean +/- SD. Though the Independent sample 't' test shows the difference in oxygen saturation to be statistically significant(p<0.05) at measured time points, the difference is clinically insignificant as the lowest spo2 being 98% is well beyond defined safe limits. No treatment was required for this fall in spo2.

<u>Table 15:-</u> Comparison of study groups based on difference between heart rate of patients at the baseline(pre-induction), and heart rate after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins

Parameters		RC			R		
(per min)	Median	Percentile 25	Percentile 75	Median	Percentile 25	Percentile 75	p-value
Intraoperative hemodymanics (baseline-after induction) HR	0.0	0.0 0.0		0.0 0.0		0.0	1.000
Intraoperative hemodymanics (baseline-after securing airway) HR	0.0	-18.0	0.0	0.0	0.0	0.0	0.058
Intraoperative hemodymanics (baseline-after skin incision) HR	0.0	-5.0	0.0	0.0	0.0	0.0	0.191
Intraoperative hemodymanics (baseline-15mins) HR	0.0	-1.0	0.0	0.0	0.0	0.0	0.100
Intraoperative hemodymanics (baseline-30mins) HR	0.0	0.0	0.0	0.0	0.0	0.0	0.498
Intraoperative hemodymanics (baseline-45mins) HR	0.0	0.0	0.0	0.0	0.0	0.0	0.698
Intraoperative hemodymanics (baseline-1hr) HR	0.0	-1.0	0.0	0.0	0.0	0.0	0.139
Intraoperative hemodymanics (baseline-75mins) HR	0.0	-1.0	0.0	0.0	0.0	0.0	0.097
Intraoperative hemodymanics (baseline-90mins) HR	0.0	-1.0	0.0	0.0	0.0	0.0	0.249

The above table shows the difference between heart rate of patients of group RC and R, at the baseline(pre-induction), and heart rate after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above.Mann-Whitney U test and Independent sample 't' test is used to compare them. The differences have been found to be statistically insignificant(p>0.05).




**Figure 20:-**Comparison of median heart rate(per min) of patients of group RC(group 1) and group R(group 2).

<u>Table 16:-</u> Comparison of study groups based on difference between systolic blood pressure of patients at the baseline(pre-induction),and systolic blood pressure after induction,after securing airway,at skin incision,at 15mins,at 30mins,at 45 mins, at 1hr,at 75mins and at 90mins

Parameters		RC			R		
(mmHg)	Median	Percentile 25	Percentile 75	Median	Percentile 25	Percentile 75	p-value
Intraoperative hemodynamics (baseline-after induction) SBP	0.0	0.0	0.0	0.0	0.0	0.0	0.345
Intraoperative hemodynamics (baseline-after securing airway) SBP	0.0	-9.0	0.0	0.0	0.0	0.0	0.139
Intraoperative hemodynamics (baseline-after skin incision) SBP	0.0	0.0	4.0	0.0	0.0	0.0	0.207
Intraoperative hemodynamics (baseline-15mins) SBP	0.0	0.0	0.0	0.0	0.0	0.0	0.498
Intraoperative hemodynamics (baseline-30mins) SBP	0.0	-1.0	0.0	0.0	0.0	0.0	0.191
Intraoperative hemodynamics (baseline-45mins) SBP	0.0	-1.0	0.0	0.0	0.0	0.0	0.339
Intraoperative hemodynamics (baseline-1hr) SBP	0.0	-2.0	0.0	0.0	0.0	0.0	0.339
Intraoperative hemodynamics (baseline-75mins) SBP	0.0	-1.0	0.0	0.0	0.0	0.0	0.257
Intraoperative hemodynamics (baseline-90mins) SBP	0.0	-1.0	0.0	0.0	0.0	0.0	0.429

The above table shows the difference between systolic blood pressure of patients of group RC and R, at the baseline(pre-induction), and systolic blood pressure after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above.Mann-Whitney U test and Independent sample 't' test is used to compare them. The differences have been found to be statistically insignificant(p>0.05).




**Figure 21:-**Comparison of median systolic blood pressure(mmHg) of patients of group RC(group 1) and group R(group 2).

<u>Table 17:-</u> Comparison of study groups based on difference between diastolic blood pressure of patients at the baseline(pre-induction), and diastolic blood pressure after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins

Parameters		RC			R				
(mmHg)	Median	Percentile 25	Percentile 75	Median	Percentile 25	Percentile 75	p-value		
Intraoperative hemodynamics (baseline-after induction) DBP	0.0	0.0	0.0	0.0	0.0	0.0	0.143		
Intraoperative hemodynamics (baseline-after securing airway) DBP	0.0 -6.0		0.0	0.0	0.0	0.0	0.212		
Intraoperative hemodynamics (baseline-after skin incision) DBP	0.0 0.0		2.0	0.0	0.0	0.0	0.106		
Intraoperative hemodynamics (baseline-15mins) DBP	0.0 0.0		0.0	0.0	0.0	0.0	0.428		
Intraoperative hemodynamics (baseline-30mins) DBP	0.0 -1.0		0.0	0.0	0.0	0.0	0.291		
Intraoperative hemodynamics (baseline-45mins) DBP		-1.0	0.0	0.0	0.0	0.0	0.249		
Intraoperative hemodynamics (baseline-1hr) DBP	0.0	-2.0	0.0	0.0	0.0	0.0	0.439		
Intraoperative hemodynamics (baseline-75mins) DBP	0.0 -1.0		0.0	0.0	0.0	0.0	0.167		
Intraoperative hemodynamics (baseline-90mins) DBP	0.0	-1.0	0.0	0.0	0.0	0.0	0.239		

The above table shows the difference between diastolic blood pressure of patients of group RC and R, at the baseline(pre-induction), and diastolic blood pressure after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above.Mann-Whitney U test and Independent sample 't' test is used to compare them. The differences have been found to be statistically insignificant(p>0.05).




<u>Figure 22:-</u> Comparison of median diastolic blood pressure(mmHg) of patients of group RC(group 1) and group R(group 2).

<u>Table 18:-</u> Comparison of study groups based on difference between mean arterial blood pressure of patients at the baseline(pre-induction), and mean arterial blood pressure after induction, after securing airway, at skin incision, at 15 mins, at 30 mins, at 45 mins, at 1 hr, at 75 mins and at 90 mins

	Group										
		RC			R						
Parameters (mmHg)	Median	Percentile 25	Percentile 75	Median	Percentile 25	Percentile 75	p-value				
Intraoperative hemodynamics (baseline-after induction) MAP	0.0	0.0	0.0	0.0	0.0	0.0	0.397				
Intraoperative hemodynamics (baseline-after securing airway) MAP	0.0	-3.0	0.0	0.0	0.0	0.0	0.138				
Intraoperative hemodynamics (baseline-after skin incision) MAP	0.0	0.0	3.3	0.0	0.0	0.0	0.477				
Intraoperative hemodynamics (baseline-15mins) MAP	0.0	0.0	0.7	0.0	0.0	0.0	0.477				
Intraoperative hemodynamics (baseline-30mins) MAP	0.0	-0.3	0.0	0.0	0.0	0.0	0.063				
Intraoperative hemodynamics (baseline-45mins) MAP	0.0	0.0	0.3	0.0	0.0	0.0	0.363				
Intraoperative hemodynamics (baseline-1hr) MAP	0.0	-1.3	0.0	0.0	0.0	0.0	0.228				
Intraoperative hemodynamics (baseline-75mins) MAP	0.0	-1.0	0.0	0.0	0.0	0.0	0.171				
Intraoperative hemodynamics (baseline-90mins) MAP	0.0	-1.0	0.0	0.0	0.0	0.0	0.171				

The above table shows the difference between mean arterial blood pressure of patients of group RC and R, at the baseline(pre-induction), and mean arterial blood pressure after induction, after securing airway, at skin incision, at 15mins, at 30mins, at 45 mins, at 1hr, at 75mins and at 90mins, calculated as median.Q1(25th percentile),Q3(75th percentile) and p-values are mentioned above. Mann-Whitney U test and Independent sample 't' test is used to compare them. The differences have been found to be statistically insignificant(p>0.05).



**Figure 23:-**Comparison of median MAP (mmHg) of patients of group RC (group 1) and group R (group 2).

Six patients of RC group(at 8hours, 15hours, 16hours, 20hours, 21hours, and 22hours) and twelve patients of R group(at 3hours, 5hours, 6hours, 7hours, 8hours, 9hours, 12hours, 16hours, 18hours, 21hours,23hours,and 24hours) complained of pain in first 24hours of postoperative period. Rescue analgesic injection Diclofenac 1.5 mg/kg intravenously has been given at the above mentioned time points. There is no other adverse effects/complications of ESP block in both the study groups.

# **DISCUSSION**

In general, the postoperative phase following breast surgeries is very painful, especially in the first few days. In addition to promoting early ambulation and hospital release, providing enough analgesia for acute postoperative pain can enhance functional outcomes and stop the onset of chronic pain. For the effective relief of initial postoperative pain following MRM surgery, a wide range of IV and oral pharmaceutical alternatives, including opioids, nonsteroidal anti-inflammatory medications (NSAIDs), acetaminophen, etc., are available. Each of these medications has unique benefits and drawbacks, limiting the extent to which they can be used universally. Multimodal pain management strategies that take advantage of the current pharmacological choices have shown to improve pain management while reducing the need for opioids.<sup>[3]</sup>

The 2016 introduction of the ESP block piqued the curiosity of numerous nerve block specialists. It has been proven to be useful in delivering postoperative analgesia following a variety of operations, including breast surgery. Clonidine's role as an adjuvant in the ESP block for postoperative analgesia following breast operations has been evaluated in a few systematic reviews and metaanalyses that have been published. These assessments, though, were constrained by the inclusion of a scant number of research that qualified. As a result, we designed a trial to determine whether clonidine, in combination with 0.5% ropivacaine, is an effective analgesic after breast surgery.

The present study has enrolled seventy-two female patients, aged between 18 to 65 years, belonging to ASA physical status class I and/or II and scheduled for modified radical mastectomy surgery. Our aim is to determine the efficacy of using clonidine as an adjuvant to 0.5%Ropivacaine in erector spinae plane block for post operative analgesia in breast surgeries. The primary objective is to evaluate the analgesic efficacy of clonidine as an adjuvant in Erector Spinae Plane block in terms of duration of analgesia defined as time to first rescue analgesic(patient demand/VAS greater or equal to 4) after breast surgeries. Secondary objectives include onset of sensory block(Block completion to grade 1 sensory block), number of dermatomes blocked, duration of sensory block(ESP block to Onset of pain), quality of analgesia(Visual Analogue Scale), total analgesic requirement in 24 hr postoperatively, and adverse effects/complications if any.

Thirty-six patients are enrolled in each group. All the patients have received the allocated intervention and have been followed up to 24hours. There is no lost to follow up and all the patient's data are analysed as per the randomized group.

#### PATIENT DEMOGRAPHICS

#### Age

In our study, mean age of patients of both groups are compared and no statistically significant difference has been found between them(P>0.05).

#### Body weight

In our study,mean body weight of patients of both groups are compared and no statistically significant difference has been found between them(P>0.05).

#### Height

In our study, mean height of patients of both groups are compared and no statistically significant difference has been found between them (P>0.05).

#### PRIMARY OBJECTIVE

#### Time to first rescue analgesic(patient demand/VAS greater or equal to 4)

In our study, median time to first rescue analgesic is 16 hours in RC and 9 hours in R group. p-value is 0.400 as found in Mann-Whitney U test and 0.925 as found in Chi-square test. This suggests no significant difference in the duration of analgesia defined as time to first rescue analgesic between patients who received clonidine as adjuvant to 0.5% ropivacaine and patients who received 0.5% ropivacaine alone. Studies done by Kalyani *et al*, Daniel M.*et al* and Kelika *et al* contradict our finding.

Kalyani *et al*<sup>[10]</sup> conducted a RCT on 60 adult patients posted for upper limb surgeries under single shot supraclavicular block by dividing them into two groups, one receiving clonidine along with 0.75% Ropivacaine and the other receiving 0.75% Ropivacaine alone and found that the duration of analgesia was prolonged in patients receiving clonidine (878.33  $\pm$  89.955 min), than the group who didn't receive clonidine(613.10  $\pm$  51.797 min).

Daniel M.et al [11] conducted a RCT on 1054 adult patients posted for surgeries without general anaesthesia(solely on peripheral nerve blocks), in which test group(573 patients) were

given single shot local anaesthetic with clonidine and local anaesthetic alone for the control group(481 patients). In controls, duration of postoperative analgesia (time to first rescue analgesic) was on average 461 min (range, 128 to 1,151 min). Clonidine significantly increased the duration (586min) (95% CI 74–169; P < 0.001).

Kelika *et al* <sup>[12]</sup> conducted a study on ninety adult patients posted for upper limb orthopedic surgery under supraclavicular brachial plexus block and were divided into two groups. Test group received clonidine as adjuvant with 0.5% bupivacaine and the other group received tramadol as adjuvant. The time for rescue analgesia was the longest in patients who received clonidine (491.8  $\pm$  33.9 min) whereas for tramadol it was (313.3  $\pm$  21.4 min), which was statistically significant (P < 0.001).

We also observed increased time to first rescue analgesic and reduced number of rescue analgesic in few of our patients but the difference was not statistically significant. One of the reasons could be that in benefit has been observed in peripheral nerve blocks as in the above mentioned studies whereas in facial plane blocks such as ESP volume of drug is more important than the role of adjuvants. Not only the role of adjuvant has been debatable but studies have also shown that varying concentration of local anaesthetic does not have an effect on postoperative analgesia. One such study the effectiveness of two different concentrations of ropivacaine (0.5% versus 0.2%) given via transverse abdominis plane (TAP) block was comparable in providing postoperative analgesia for patients undergoing appendectomy. [40]

#### **SECONDARY OBJECTIVES**

#### Onset of sensory block(Block completion to Grade 1 sensory block)

In our study, there is no statistically significant difference between time to sensory block onset of RC and the R group(P-value 0.513). This suggests that the onset of sensory block is similar in patients receiving Clonidine as adjuvant to 0.5% ropivacaine and in patients receiving ropivacaine alone. But the studies conducted by Daniel M et al, Kelika et al, and Anil *et al* contradicts our finding on onset of sensory block.

Daniel M.et al [11] conducted a RCT on 1054 adult patients posted for surgeries without general anaesthesia(solely on peripheral nerve blocks), in which test group(573 patients) were given single shot local anaesthetic with clonidine and local anaesthetic alone for the control

group(481 patients).In controls, average time to onset of sensory block was 15 min (range, 4–26). Clonidine significantly shortened that time;(12.5 min) (95% CI –4.1 to –0.4; P  $\,$  0.02). Kelika *et al*  $^{[12]}$  conducted a study on ninety adult patients posted for upper limb orthopedic surgery under supraclavicular brachial plexus block and were divided into two groups. Test group received clonidine as adjuvant with 0.5% bupivacaine and the other group received tramadol as adjuvant.Patients who received clonidine had the shortest time for the onset of blockade, i.e. (396.0  $\pm$  60.2 s) with a P < 0.01.The difference in the onset time was statistically significant between the two groups.

Anil *et al* <sup>[13]</sup> conducted a RCT on twenty-four patients posted for upper extremity surgery under ultrasound-guided axillary brachial plexus block (ABPB) with 20 mL of lidocaine 2% with 1:200,000 epinephrine plus 2 mL of either normal saline 0.9% (Group 1) or a mixture of clonidine 1  $\mu$ g/kg and normal saline 0.9% (Group 2).The median (IQR) overall onset time of sensory block was significantly shorter in Group 2 vs. Group 1 (5 (5–7.5) min vs. 10 (8.8–12.5) min; p < 0.001) and (5 (2.5–7.5) min vs. 7.5 (6.3–7.5) min; p = 0.001), respectively. So, the addition of clonidine to lidocaine with epinephrine resulted in shorter onset time.

#### Number of dermatomes blocked

In our study, there is no statistically significant difference between number of dermatomes blocked, of RC and R group(P-value 0.606). This suggests that the mean number of dermatomes blocked is similar in patients receiving Clonidine as adjuvant to 0.5% ropivacaine and in patients receiving ropivacaine alone. One of the probable reasons could be that in fascial plane blocks such as ESP volume of drug is more important than the role of adjuvants.

#### Duration of sensory block(ESP block to onset of pain)

In our study, six patients RC group and twelve patients in R group complained of pain(VAS greater or equal to 4) requiring rescue analgesic. In RC group, earliest time point when patient complained of pain is 8hours and for R group is 3hours in postoperative period. This suggests that duration of sensory block (defined as time of ESP block application to onset of pain) in patients who received clonidine as adjuvant to 0.5% ropivacaine compared to patients who received 0.5% ropivacaine alone is statistically insignificant. Hence, the duration of sensory block is comparable between the two groups. Kalyani *et al*, Daniel M.*et al*, Kelika *et al*, Duma *et al* and Anil *et al* also came to the same conclusion in their studies.

Kalyani *et al*<sup>[10]</sup> conducted a RCT on 60 adult patients posted for upper limb surgeries under single shot supraclavicular block by dividing them into two groups, one receiving clonidine along with 0.75% Ropivacaine and the other receiving 0.75% Ropivacaine alone and found that the duration of sensory block was  $(703.83 \pm 42.90)$  min in clonidine group when compared to  $(556.38 \pm 37.96)$  min in control group.

Daniel M.et al [11] conducted a RCT on 1054 adult patients posted for surgeries without general anaesthesia(solely on peripheral nerve blocks), in which test group(573 patients) were given single shot local anaesthetic with clonidine and local anaesthetic alone for the control group(481 patients). In controls, the average duration of sensory block was 269\min. Clonidine significantly prolonged the duration(350min) (95% CI 37–111; P < 0.001).

Duma *et al* <sup>[14]</sup> conducted a RCT on forty adult patients who were given axillary brachial plexus block,in which twenty patients of test group was given 0.5% levobupivacaine with clonidine and the other group was given levobupivacaine alone. It was found that the levobupivacaine-clonidine group appeared to have a significantly longer duration of sensory block than the other group 1340(606–2074) min in the levobupivacaine-clonidine group and 1065(912–1218) min in the levobupivacaine group.

Kelika *et al* <sup>[12]</sup> conducted a study on ninety adult patients posted for upper limb orthopedic surgery under supraclavicular brachial plexus block and were divided into two groups. Test group received clonidine as adjuvant with 0.5% bupivacaine and the other group received tramadol as adjuvant. The duration of sensory block was 320min in test group whereas it was 250min in control group, which was statistically significant.

Anil *et al* <sup>[13]</sup> conducted a RCT on twenty-four patients posted for upper extremity surgery under ultrasound-guided axillary brachial plexus block (ABPB) with 20 mL of lidocaine 2% with 1:200,000 epinephrine plus 2 mL of either normal saline 0.9% (Group 1) or a mixture of clonidine 1 μg/kg and normal saline 0.9% (Group 2). The median (IQR) overall duration of sensory and motor block was signifificantly longer in Group 2 vs. Group 1 (225 (200–231) min vs. 168 (148–190) min; p < 0.001) and (225 (208–231) min vs. 168(148–186) min; p < 0.001), respectively. So, the addition of clonidine to lidocaine with epinephrine resulted in prolonged duration of sensory block.

#### Quality of analgesia(Visual Analogue Scale)

In our study, the difference between resting VAS scores of RC and R groups has been found to be statistically significant at 90minutes postoperatively(P<0.05) but is insignificant at rest of the major time points. Although VAS(resting) at 90 minutes is significant statistically, but is insignificant clinically(Mean VAS at 90mins being 2.1 and 2.9 for RC and R groups respectively), as they are beyond the criteria to administer rescue analgesic(VAS greater or equal to 4). This suggests that clonidine as adjuvant has no significant effect on the quality of analgesia. Study done by Yogesh *et al* contradicts our finding.

Yogesh *et al* <sup>[15]</sup> conducted a study on ninety adult patients undergoing elective upper limb surgeries under supraclavicular block divided into three groups: Group N: Received injection bupivacaine 0.5% 15 ml + injection. Lignocaine with adrenaline 2% 15 ml + normal saline 0.5 ml. Group D: 1  $\mu$ g/kg dexmedetomidine. Group C: 1.5  $\mu$ g/kg clonidine as studied drug in place of normal saline. VAS score in the post-operative period at 6hours was higher in Group N (5.12  $\pm$  0.68) when compared to Group C (4.5  $\pm$  0.73) and Group D (2.07  $\pm$  0.94), respectively. So,the addition of Clonidine proved to have better patient satisfaction than bupivacaine alone.

#### Total analysic requirement in 24 hr postoperatively

In our study, the total analgesic requirement in the group receiving clonidine as adjuvant is the same as the group receiving ropivacaine alone. Six patients in RC group and twelve patients in R group required rescue analgesic. The number of patients requiring rescue analgesic in Group R is twice the number of patients requiring rescue analgesic in RC group but the difference between both the groups is statistically insignificant (p>0.05). Hence there is no significant difference between the total analgesic consumption between both the groups.

#### Vitals since ESP block application

The comparison of vitals of patients since ESP block application, every five minutes till thirty minutes showed that HR, SBP, DBP and MAP are similar in the test group and control group except for oxygen saturation which was higher in control group (the difference is clinically insignificant as the lowest SPO2 being 98% is well beyond defined safe limits). This suggests that addition of Clonidine to Ropivacaine did not have significant effect on the vitals of the patients since time to ESP block application in our study.

#### Intraoperative hemodynamics

The comparison of vitals of patients since the start of surgery, after induction, after securing airway, at skin incision, then every fifteen minutes till ninety minutes showed that HR, SBP, DBP and MAP are similar in the test group and control group. This suggests that addition of Clonidine to Ropivacaine did not have significant effect on the intraoperative hemodynamics of the patients in our study.

# Adverse effects/complications if any

There has been no adverse effects/complications of ESP block, like hypotension, bradycardia, hematoma, pneumothorax, sedation, nausea, vomitting, dry mouth in both the study groups.

# **CONCLUSION**

There is no effect of addition of Clonidine as an adjuvant to 0.5% Ropivacaine in ESP block on the time to first rescue analgesic, time to sensory block onset, the quality of analgesia, duration od sensory block, number of dermatomes blocked and total analgesic requirement in 24hours. No adverse effects/complications are noted.

#### STRENGTHS OF OUR STUDY

- 1. All the blocks were performed by a single anaesthesiologist throughout the study period.
- 2. All the blocks were performed using ultrasound guidance.
- 3. Randomization and allocation concealment was strictly followed throughout the study.

#### LIMITATIONS OF OUR STUDY

- 1. We could not assess the other benefits of adequate pain control (functional outcome, early ambulation, early discharge, and development of chronic pain).
- 2. Although sample size calculation was based on the data from the published literature and clinically important reasonable assumption, we believe that further studies with multicentric design and large sample size are required to reciprocate the findings of our study.

# **BIBLIOGRAPHY**

- Junbao Fu, BM, Guangmeng Zhang, BM, Yanming Qiu, BM; Erector spinae plane block for postoperative pain and recovery in hepatectomy; Fu et al. Medicine (2020) 99:41 Medicine
- Rosemary Hickey, M.D.," Joan Hoffman, R.N., M.S.N., j Somayaii Ramamurthy, M.D.jA; Comparison of Ropiracaine O.5% and Bupivacaine O.S% for Brachial Plexus Block; Anesthesiology 74:639-642, 1991
- 3. Mohamed A. Bakr, MD1, Sahar A. Mohamed, MD2, Mohamad F. Mohamad, MD2, Montaser A. Mohamed, MD2, Fatma A. El Sherif, MD2, Eman Mosad, MD2, and Mohammed F. Abdel-Hamed, MSc2;Effect of Dexmedetomidine Added to Modified Pectoral Block on Postoperative Pain and Stress Response in Patient Undergoing Modified Radical Mastectomy;Pain Physician 2018; 21:E87-E96 ISSN 2150-1149
- 4. R. W. Leong, 1 E. S. J. Tan, 1 S. N. Wong, 2 K. H. Tan3, 4,5 and C. W. Liu; Effificacy of erector spinae plane block for analgesia in breast surgery: a systematic review and meta-analysis; doi:10.1111/anae.15164.
- 5. Zhixin Gao, Yimin Xiao, Qing Wang, Yuanhai Li;Comparison of dexmedetomidine and dexamethasone as adjuvant for ropivacaine in ultrasound-guided erector spinae plane block for video-assisted thoracoscopic lobectomy surgery: a randomized, double-blind, placebo-controlled trial;Ann Transl Med 2019;7(22):668
- 6. Sarita S Swami, Varshali M Keniya, Sushma D Ladi, and Ruchika Rao; Comparison of dexmedetomidine and clonidine (α2 agonist drugs) as an adjuvant to local anaesthesia in supraclavicular brachial plexus block: A randomised double-blind prospective study; Indian J Anaesth. 2012 May-Jun; 56(3): 243–249.
- 7. Pablo Kot1, Pablo Rodriguez1, Manuel Granell1, Beatriz Cano2, Lucas Rovira1, Javier Morales1, Ana Broseta1, and Jose De Andrés1; The erector spinae plane block: a narrative review; Korean J Anesthesiol 2019 June 72(3): 209-220.
- 8. Jingxiong Zhang1, Yuting He1, Shi Wang1, Zhengjie Chen1, Yu Zhang1, Yuan Gao1, Quanguang Wang1, Yun Xia2, Thomas J. Papadimos1,2 and Riyong Zhou1; The erector spinae plane block causes only cutaneous sensory loss on ipsilateral posterior thorax: a prospective observational volunteer study; Zhang et al. BMC Anesthesiology (2020) 20:88

- Laura Bertini, M.D., Vincenzo Tagariello, M.D., Stefania Mancini, M.D., Alma Ciaschi, M.D., Carla Maria Posteraro, M.D., Pia Di Benedetto, M.D., and Ornella Martini, M.D.;0.75% and 0.5% Ropivacaine for Axillary Brachial Plexus Block: A Clinical Comparison With 0.5 % Bupivacaine;Regional Anesthesia and Pain Medicine 24(6): 514-518, 1999.
- 10. Kalyani Nilesh Patil, Noopur Dasmit Singh; Clonidine as an adjuvant to ropivacaine-induced supraclavicular brachial plexus block for upper limb surgeries; Journal of Anaesthesiology Clinical Pharmacology | July-September 2015 | Vol 31 | Issue 3
- 11. Daniel M. Po" pping, M.D.,\* Nadia Elia, M.D., M.Sc.,† Emmanuel Marret, M.D.,‡ Manuel Wenk, M.D.,\* Martin R. Trame`r, M.D., D.Phil;Clonidine as an Adjuvant to Local Anesthetics for Peripheral Nerve and Plexus Blocks;Anesthesiology 2009; 111:406–15
- 12. Kelika, Prakash; Arun, Jamkar Maya; Evaluation of clonidine as an adjuvant to brachial plexus block and its comparison with tramadol; Journal of Anaesthesiology Clinical Pharmacology 33(2):p 197-202, Apr–Jun 2017.
- 13. Anil Ranganath 1,\*, Tomas Hitka 2 and Gabriella Iohom; Effects of Clonidine as an Adjuvant to Lidocaine with Epinephrine in Ultrasound Guided Axillary Brachial Plexus Block: A Randomised Controlled Trial; J. Clin.Med. 2021, 10, 4181.
- 14. A. Duma\*, B. Urbanek, C. Sitzwohl, A. Kreiger, M. Zimpfer and S. Kapral; Clonidine as an adjuvant to local anaesthetic axillary brachial plexus block: a randomized, controlled study; British Journal of Anaesthesia 94 (1): 112–16 (2005).
- 15. Yogesh Tilkar, Sangeeta Bansal Agarwal, Rahul Gupta, Sanjeevani Karmalkar, Prabha Khatri, Neetu Gupta;The efficacy and safety of clonidine and dexmedetomidine as an adjuvant in supraclavicular brachial plexus block for elective upper limb surgery;International Journal of Medical Science and Public Health;2017/vol 6/issue 8.
- 16. Danxu Ma Huilong Ren Xueyang Li Huili Li Jia Jiang Anshi Wu Yun Wang;Ultrasound-guided single erector spinae plane block versus thoracic paravertebral block for patients undergoing video-assisted thoracoscopic lobectomy: a randomized controlled trial;reserch square;10.21203/rs.2.14933/v1
- 17. Noriko Tanaka, MD, PhD, Hironobu Ueshima, MD, PhD, Hiroshi Otake, MD, PhD, Professor; Erector spinae plane block for combined lovectomy and radical mastectomys; Journal of Clinical Anesthesia 45 (2018) 27–28

- 18. Essam F.Abdelgalel MD\*, Farahat I.Ahmed MD; Comparative study of ropivacaine with ropivacaine plus dexmedetomidine for pectoral nerves block (Pecs II block) in unilateral breast surgery; Research and Opinion in Anesthesia & Intensive Care Volume 2
- 19. Kjartan Eskjaer Hannig Christian Jessen,1 Uday Kant Soni,1 Jens Børglum and Thomas Fichtner Bendtsen;Erector Spinae Plane Block for Elective Laparoscopic Cholecystectomy in the Ambulatory Surgical Setting;Case Reports in Anesthesiology Volume 2018, Article ID 5492527
- 20. Yasuko Taketa , Yumi Irisawa, Taro Fujitani; Comparison of ultrasound-guided erector spinae plane block and thoracic paravertebral block for postoperative analgesia after video-assisted thoracic surgery: a randomized controlled non-inferiority clinical trial; Taketa Y, et al. Reg Anesth Pain Med 2020; 45:10–15. doi:10.1136/rapm-2019-100827
- 21. Mauricio Forero, MD, FIPP,\* Sanjib D. Adhikary, MD,† Hector Lopez, MD,‡ Calvin Tsui, BMSc,§ and Ki Jinn Chin;The Erector Spinae Plane Block A Novel Analgesic Technique in Thoracic Neuropathic Pain;Reg Anesth Pain Med 2016;41: 621–627.
- 22. Anju Gupta, Nishkarsh Gupta1, Arindam Choudhury2, Nidhi Agrawal; Erector Spinae Plane Block using Clonidine as an Adjuvant for Excision of Chest Wall Tumor in a Pediatric Patient; 10.4103/aca. ACA\_188\_18
- 23. Başak Altıparmaka,\* , Melike Korkmaz Tokerb , Ali İhsan Uysalb , Mustafa Turana, Semra Gümüş Demirbilek;Comparison of the effects of modified pectoral nerve block and erector spinae plane block on postoperative opioid consumption and pain scores of patients after radical mastectomy surgery: A prospective, randomized, controlled trial;Journal of Clinical Anesthesia 54 (2019) 61–65
- 24. K. J. Chin,1 S. Adhikary,2 N. Sarwani3 and M. Forero;The analgesic effificacy of pre-operative bilateral erector spinae plane (ESP) blocks in patients having ventral hernia repair;Anaesthesia 2017, 72, 452–460 doi:10.1111/anae.13814
- 25. Junbao Fu, BM, Guangmeng Zhang, BM, Yanming Qiu, BM; Erector spinae plane block for postoperative pain and recovery in hepatectomy; Fu et al. Medicine (2020) 99:41
- 26. Thiago Mamoru Sakae, Luiz Henrique Ide Yamauchi a,c,d, Augusto Key Karazawa Takaschimaa,c,d, Julio C. Brandão d, Roberto Henrique Benedetti;Comparison between erector spinal plane block and epidural block techniques for postoperative analgesia in open cholecystectomies: a randomized clinical trial;Rev Bras Anestesiol. 2020;70(1):22---27

- 27. Ruggero M. CORSO 1, Steven LEE 2, Jacek WOJTCZAK 3, Davide CATTANO 2;Use of the ultrasound-guided erector spinae plane block in breast surgery;MinervaAnestesiologica 2017 October;83(10):1112-3
- 28. Ban Tsui, M.D., Farrukh Munshey, M.D., Thomas J. Caruso, M.D., Ellen Y. Wang, M.D. Stanford University, Stanford, California, United States; Technical Description and Early Experiences with the Use of Continuous Erector Spinae Plane Blocks in Children
- 29. S. Kulhari1, N. Bharti1,\*, I. Bala1, S. Arora1 and G. Singh; Effificacy of pectoral nerve block versus thoracic paravertebral block for postoperative analgesia after radical mastectomy: a randomized controlled trial; British Journal of Anaesthesia, 117 (3): 382–6 (2016)
- 30. Cassandra Hoffmann a , Alain Harb a , Elie Geara a , Eric Devaney a , b , Shelley Ohliger; Single injection Erector Spinae Plane block for vascular ring repair: Is a catheter required? Journal of Pediatric Surgery Case Reports 60 (2020) 101553
- 31. Reymi Marseela Abdul Jalil 1, Nurlia Yahya 1 \*, Omar Sulaiman 2, Wan Rahiza Wan Mat 1, Rufifinah Teo 1, Azarinah Izaham 1, Raha Abdul Rahman; Comparing the effectiveness of ropivacaine 0.5% versus ropivacaine 0.2% for transabdominis plane block in providing postoperative analgesia after appendectomy; Acta Anaesthesiologica Taiwanica 52 (2014) 49e53
- 32. Swati Singh, Neeraj Kumar Chowdhary; Erector spinae plane block an effective block for post-operative analgesia in modified radical mastectomy; Indian Journal of Anaesthesia; Volume 62 | Issue 2 | February 2018
- 33. Sandeep Krishnan; Erector Spinae Plane Block; / ArticleLibrary/viewarticle/76369
- 34. Jakob Hessel Andersen1\*, Pia Jaeger2, Tobias Laier Sonne1, Jørgen Berg Dahl3, Ole Mathiesen1, Ulrik Grevstad; Clonidine used as a perineural adjuvant to ropivacaine, does not prolong the duration of sensory block when controlling for systemic effects: A paired, blinded, randomized trial in healthy volunteers; PLoS ONE 12(9): e0181351
- 35. Chandni Sinha, Amarjeet Kumar, Ajeet Kumar, Chandrakant Prasad, Prashant Kumar Singh, and Diti Priya; Pectoral nerve versus erector spinae block for breast surgeries: A randomised controlled trial; Indian J Anaesth. 2019 Aug; 63(8): 617–622.
- 36. Swati Singh, Gunjan Kumar, Akhileshwar;Ultrasound-guided erector spinae plane block for postoperative analgesia in modified radical mastectomy: A randomised control study;Indian J Anaesth 2019;63:200-4.

- 37. Amit Goyal, Sriganesh Kamath, Pramod Kalgudi, Mathangi Krishnakumar;Perioperative analgesia with erector spinae plane block for cervical spine instrumentation surgery;Saudi Journal of Anesthesia / Volume 14 / Issue 2 / April-June 2020
- 38. Yavuz Gürkan, Can Aksu\*, Alparslan Kuş, Ufuk H. Yörükoğlu, Cennet T. K;Ultrasound guided erector spinae plane block reduces postoperative opioid consumption following breast surgery: A randomized controlled study;Journal of Clinical Anesthesia 50 (2018) 65–68
- 39. Josh P. Melvin, MD . Rudolph J. Schrot, MD, MAS, FAANS . George M. Chu, MD . Ki Jinn Chin, MBBS (Hons), MMed, FRCPC;Low thoracic erector spinae plane block for perioperative analgesia in lumbosacral spine surgery: a case series;Can J Anesth/J Can Anesth (2018) 65:1057–1065
- 40. Abdul Jalil RM, Yahya N, Sulaiman O, Wan Mat WR, Teo R, Izaham A, Rahman AR. Comparing the effectiveness of ropivacaine 0.5% versus ropivacaine 0.2% for transabdominis plane block in providing postoperative analgesia after appendectomy. Acta Anaesthesiologica Taiwanica 2014; 52(2): 49-5

# **ANNEXURES**

## ANNEXURE - 1

## INSTITUTIONAL ETHICS COMMITTEE CERTIFICATE



# अखिल भारतीय आयुर्विज्ञान संस्थान, जोधपुर All India Institute of Medical Sciences, Jodhpur संस्थागत नैतिकता समिति Institutional Ethics Committee

No. AIIMS/IEC/2021/ 2412

# ETHICAL CLEARANCE CERTIFICATE

Date: 12/03/2021

Certificate Reference Number: AIIMS/IEC/2021/3327

Project title: "To evaluate the effect of clonidine as an adjuvant to 0.5% ropivacaine in ESP block for post operative analgesia in breast surgeries: RCT"

Nature of Project: Research Project Submitted for Expedited Review

Submitted as: M.D. Dissertation
Student Name: Dr. Shreya Neogy
Guide: Dr. Bharat Paliwal

Co-Guide: Dr. Manoj Kamal, Dr. Pradeep Bhatia, Dr. Sadik Mohammed & Dr. Rakesh

Kumar

Institutional Ethics Committee after thorough consideration accorded its approval on above project.

The investigator may therefore commence the research from the date of this certificate, using the reference number indicated above.

Please note that the AIIMS IEC must be informed immediately of:

- · Any material change in the conditions or undertakings mentioned in the document.
- Any material breaches of ethical undertakings or events that impact upon the ethical conduct of the research.
- In case of any issue related to compensation, the responsibility lies with the Investigator and Co-Investigators.

The Principal Investigator must report to the AIIMS IEC in the prescribed format, where applicable, bi-annually, and at the end of the project, in respect of ethical compliance.

AIIMS IEC retains the right to withdraw or amend this if:

- Any unethical principle or practices are revealed or suspected
- · Relevant information has been withheld or misrepresented

AIIMS IEC shall have an access to any information or data at any time during the course or after completion of the project.

Please Note that this approval will be rectified whenever it is possible to hold a meeting in person of the Institutional Ethics Committee. It is possible that the PI may be asked to give more clarifications or the Institutional Ethics Committee may withhold the project. The Institutional Ethics Committee is adopting this procedure due to COVID-19 (Corona Virus) situation.

If the Institutional Ethics Committee does not get back to you, this means your project has been cleared by the IEC. On behalf of Ethics Committee, I wish you success in your research.

Dr. Praveen Sharm Member Secretary

Member secretary Institutional Ethics Committee AIIMS, Jodhpur

#### <u>ANNEXURE – 2</u>

#### **Informed Consent Form**

**Title of the project:** TO EVALUATE THE EFFECT OF CLONIDINE AS AN ADJUVANT TO 0.5% ROPIVACAINE IN ESP BLOCK FOR POST OPERATIVE ANALGESIA IN BREAST SURGERIES: A RANDOMIZED CONTROLLED TRIAL

Name of the Principal Investigator: Dr.Shreya Neogy Patient/Volunteer Identification No.:\_\_\_\_\_ I, \_\_\_\_\_\_ S/o or D/o\_\_\_\_\_ give my full, free, voluntary consent to be a part of the study: 'TO EVALUATE THE EFFECT OF CLONIDINE AS AN ADJUVANT TO 0.5% ROPIVACAINE IN ESP BLOCK FOR POST OPERATIVE ANALGESIA IN BREAST SURGERIES:A RANDOMIZED CONTROLLED TRIAL' the procedure and nature of which has been explained to me in my own language to my full satisfaction. I confirm that I have had the opportunity to ask questions. I understand that my participation is voluntary and I am aware of my right to opt out of the study at any time without giving any reason. I understand that the information collected about me and any of my medical records may be looked at by a responsible individual from AIIMS Jodhpur or from regulatory authorities. I give permission for these individuals to have access to my records. Date: \_\_\_\_\_ Signature/Left thumb impression This to certify that the above consent has been obtained in my presence. Date: \_\_\_\_\_ Signature of Principal Investigator Place: \_\_\_\_\_ Witness 1 Witness 2 Signature: \_\_\_\_ Signature: Name:\_\_\_\_\_ Address:\_\_\_\_\_ Address:\_\_\_\_\_

# ANNEXURE – 3

ऑल इंडिया इंस्टिट्यूट ऑफ मैडिकल साईंसिस जोधपुर, राजस्थान

# सूचित सहमति पत्र

परियोजना का शीर्षक: TO EVALUATE THE EFFECT OF CLONIDINE AS AN ADJUVANT TO 0.5% ROPIVACAINE IN ESP BLOCK FOR POST OPERATIVE ANALGESIA IN BREAST SURGERIES:A RANDOMIZED CONTROLLED TRIAL

प्रधान अन्वेषकका नाम: Dr.Shreya Neogy		
书 <u></u>	एस/ओयाडी/ओ	आर/ओ
अध्ययन: EFFECT OF CLONIDINE AS AN	N ADJUVANT TO 0.5% ROPI	—— VACAINE IN ESP BLOCK FOR
POST OPERATIVE ANALGESIA IN BRE	EAST SURGERIES:A RANDO	OMIZED CONTROLLED TRIAL
का एक हिस्सा बनने के लिए मेरी पूर्ण, नि:शुल्क,	स्वैच्छिक सहमति, प्रक्रिया और प्रकृ	ति जिसके बारे में मुझे अपनी भाषा में
बताया गया है,मैं पुष्टि करता हूं कि मुझे प्रश्न पूछने	का अवसर मिला है।	
मैं समझता हूं कि मेरी भागीदारी स्वैच्छिक है और मु	झे किसी भी कारण दिए बिना किसी	भी समय अध्ययन से बाहर निकलने के
मेरे अधिकार की जानकारी है।		
मैं समझता हूं कि मेरे और मेरे मेडिकल रिकॉर्ड के बा	ारे में एकत्रित की गई जानकारी को ए	म्स, जोधपुर या विनियामक प्राधिकरणों
से ज़िम्मे व्यक्ति द्वारा देखा जा सकता है। मैं इन लोग	ों के लिए मेरे रिकॉर्डों तक पहुंच की	अनुमति देता हूं
रोगी / पहचानसंख्याः तारीख : जगहः हस्ताक्षर / बाएं अँगूठे का छाप		
यह प्रमाणित करने के लिए कि मेरी उपस्थिति में उ	उपरोक्त सहमति प्राप्त की गई है	
तारीख :		
जगह:		प्रधान अन्वेषक के हस्ताक्षर
1. गवाह 1	2. गवाह 2	
हस्ताक्षर:	हस्ताक्षर:	
नाम :	नाम:	_
पता :	पताः	

#### <u>ANNEXURE – 4</u>

#### **PATIENT INFORMATION SHEET**

- 1. Risks to the patients: No interventions or life-threatening procedure will be done.
- 2. Confidentiality: Your participation will be kept confidential. Your medical records will be treated with confidentiality and will be revealed only to doctors/ scientists involved in this study. The results of this study may be published in a scientific journal, but you will not be identified by name.
- 3. Provision of free treatment for research related injury. Not applicable.
- 4. Compensation of subjects for disability or death resulting from such injury: Not Applicable
- 5. Freedom of individual to participate and to withdraw from research at any time without penalty or loss of benefits to which the subject would otherwise be entitled.
- 6. You have complete freedom to participate and to withdraw from research at any time without penalty or loss of benefits to which you would otherwise be entitled.
- 7. Your participation in the study is optional and voluntary.
- 8. The copy of the results of the investigations performed will be provided to you for your record.
- 9. You can withdraw from the project at any time, and this will not affect your subsequent medical treatment or relationship with the treating physician.
- 10. Any additional expense for the project, other than your regular expenses, will not be charged from you.

#### ANNEXURE – 5

# रोगी सूचना पत्रक

- 1. रोगियों के लिए जोखिम: कोई हस्तक्षेप या जीवनधमकी प्रक्रिया नहीं की जाएगी।
- 2. गोप नी यता: आप की भागीदारी को गोप नीय रखा जाए गा।
  आप के मे डिकल रिकॉर्ड को गोप नी यता के साथ इलाज किया जाए गा और
  केवल इस अध्ययन में शामिल डॉक्टरों / वैज्ञानिकों को पता चले गा।
  इस अध्ययनके परिणाम एक वैज्ञानिक पत्रिका में प्रकाशित हो सकते हैं, लेकिन आपको नाम से पहचाना नहीं जाए गा।
- 3. अनुसंधान संबंधी चोट के लिए नि: शुल्क उपचार की व्यवस्था। लागू नहीं।
- 4. ऐसी चोट से उत्पन्न विकलांगता या मृत्यु के लिए विषयों का मुआवजा: लागू नहीं है
- 5. किसी भी समय दंड या लाभों के नुकसान के बिना किसी भी समय भाग लेने के लिए व्यक्ति को स्वतंत्रतालेने और अनुसंधान से वापस लेने के लिए स्वतंत्रता, जिसके तहत विषय अन्यथा हकदार होगा
- 6. आपको जुर्माना या लाभ के नुकसान के बिना किसी भी समय भाग लेने और अनुसंधान से वापस लेने कीपूरी आजादी है, जिस पर आप अन्यथा हकदार होंगे।
- 7. अध्ययन में आपकी भागीदारी वैकल्पिक और स्वैच्छिक है।
- 8. प्रदर्शन की जांच की परिणामों की प्रति आपके रिकॉर्ड के लिए आपको उपलब्ध कराई जाएगी।
- 9. आप किसी भी समय परियोजना से वापस ले सकते हैं, और यह आपके बाद के चिकित्सा उपचार याउपचार चिकित्सक के सा थ संबंध को प्रभावित नहीं करेगा।
- 10. परियोजना के लिए कोई भी अतिरिक्त व्यय, आपके नियमित खर्चों के अलावा, आपसे शुल्क नहीं लियाजाएगा।

#### ANNEXURE – 6

## APPENDIX-III

#### **PROFORMA**

All India Institute of Medical Sciences(AIIMS), Jodhpur Department of Anaesthesiology and Critical Care

**Thesis Title:** TO EVALUATE THE EFFECT OF CLONIDINE AS AN ADJUVANT TO 0.5%ROPIVACAINE IN ESP BLOCK FOR POST OPERATIVE ANALGESIA IN BREAST SURGERIES:A RANDOMIZED CONTROLLED TRIAL


Date:	
Patient's name:	
Age:	
Registration ID:	
Diagnosis:	
Time to Sensory block onset:	
Number of dermatomes blocked:	

Time to Block	Pulse	Systolic BP	Diastolic BP	Mean BP	SPO <sub>2</sub>	Remark
Baseline						
5 min						
10 min						
15 min						
20 min						
25 min						
30 min						

#### PATIENT SATISFACTION BY VAS SCORING:

Time	30 min	1 hr	90 min	2 hr	4 hr	6 hr
VAS(R/M)						
Rescue Analgesic (Y/N)						
Remarks						

# Time to First rescue analgesic:



## Total analgesic in 24 hours:

## Complications in 24 hrs:

Intraoperative Hemodynamics										
Time	Heart Rate	Systolic BP	Diastolic BP	Mean BP						
Baseline										
After Induction										
After Securing Airway										
At Skin Incision										
15 min										
30 min										
45 min										
1 hr										
75 min										
90 min										

# ANNEXURE – 7 MASTER CHART

Sl.No Group Date Name Age (years	Registration ID Diagnosis Diagnosis Diagnosis Time to sensory block onset (min)  Number of time to block - baseline Pulse block onset (min)  Number of demandores bloc	Time to block -   Time to bl	block - Systolic 20 min Diastolic 20 min Diastolic - 20 min Mean 20 min	block - Time to block - Time to block - 25 min Systolic 25 min Diastolic 25 min Mean 25 min Systolic 25 min Diastolic 25 min Mean 25 min Rema	Time to block - Time to block	Intraoperative   Intr	Intraoperative Intrao	perative Intraoperative Intraoperati	tive Intraoperative I	we Intraoperative Int	Intraoperative Intraoperative Intraoperative themodynamics at 75 min Diastolic at 75 min Mean 90 min Heart	et Intraoperative Intraoperative Intraoperative tat hemodynamics at hemodynamics at to 90 min Systolic 90 min Diastolic at 90 min Mean at 30min	7) VAS(MOTOR) Rescue at 30min	Remarks at 2hrs  VAS VAS Rescue (RESTING) (MOTOR) analgesic at 4hrs  Remarks at 4hrs  VAS VAS Rescue (RESTING) (MOTOR) analgesic at 4hrs  VAS (RESTING) (MOTOR) analgesic at 4hrs  VAS (RESTING) (MOTOR) analgesic at 4hrs	VAS Rescue analgesic at 9hrs (RESTINC	NG (MOTOR) Rescue Remarks (RESTING) (MOTOR) analgesic at at 12hrs at 16hrs at 16hrs	ue Remarks at 16hrs (RESTING) (MOTOR) analgesic at	Remarks (RESTING) (MOTOR) analgesic at at 20hrs (RESTING) (MOTOR) analgesic at at 24hrs at 24hrs	otal dgesic in Complications in 24 hrs
1 1 12.03.2021 RAFIKA 45	DOLCKE   DOCKE   DOC	Puseper min   Bruming   BP(mmHg)   BP(mmHg)   SpO.2(%)   Puseper min   Bruming   Bruming   Bruming   Bruming   SpO.2(%)   Remarks (per min ) Bruming   Bru	mHg) BP(mmHg) BP(mmHg) SpO2(%) Remarks Pulse(pe: 34 106 115 98 none 79 32 105 114 100 ppng 69	r min) Br(minrig) Br(minrig) Br(minrig) SpO2(%)  129 98 108 98 none  122 107 115 100 pone	Puscper min) BP(mmrig) BP(mmrig) SpU2(%) Remarks rate(per min) BP(mmHg) BP(	BP(mmHg)   rate(per min)   BP(mmHg)   BP(mmHg)   BP(mmHg)   rate(per min)   111   91   133   101   112   92   120   68   138   106   117   76	BP(mmHg) Diastolic BP(mmHg) BP(mmHg) rate(per min) BP(mmHg) BP(mmHg) BP(mmHg) min) BP(m 132 103 113 87 132 105 114 95 1: 142 90 113 66 136 106 116 68	mmHg) BP(mmHg) BP(mmHg) rate(per min) BP(mmHg) BP(mmHg) BP(mmHg) 38 106 117 87 132 105 114 132 105 114 141 141 141 141 141 141 141 141 14	fg)         rate(per min)         BP(mmHg)         BP(mmH           91         133         106           65         129         99	BP(mmHg) rate(per min)   BP(mmHg)   BP(mmHg)   BP(mmHg) rate(per min)   BP(mmHg)     BP(mmHg)   rate(per min)   BP(mmHg)	BP(mmHg) BP(mmHg) rate(per min) 107 115 88	BP(mmHg) BP(mmHg) BP(mmHg)  132 105 114 0  138 106 117 1	min (1/N)	at 4nrs at 4nrs (17/8) at onrs at onrs onrs(17/8) at 9nrs at onrs 2 3 N none 2 3 N none 2  2 2 N none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N 2 N none 2 3 N	none 2 3 N	at 24nrs at 24nrs 24nrs(1/N) analgesic 24 nr none 2 3 N none N/A Y	N/A None
2 1 13.03.2021 GOLL DEVI 00	202103000001 LEFT CA BREAST 10 5 02 110 00 07 00 pone 02 110 00 07 00	none 05 135 100 117 100 none 70 137 101 113 100 none 72 1.	11 08 102 09 100 1016 09	110 90 97 99 200	77 130 100 117 100 100E 71 142 109	07 02 110 00 07 02	110 90 97 92 110 90 97 92 1	110 90 97 92 110 90 97	92 110 90	07 92 110 90 97 92 110	90 97 92	110 90 97 0	2 N 10000 2 3 N 10000 2 3 N 10000 2 3 N	indice 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 2 3 N none 3hr	A None
5 2 14.03.2021 FINAT 40	2021091007629 LEFT CA BREAST 10 3 32 110 30 37 39 1101E 92 1110 90 37 99	1801E 92 110 90 97 99 1801E 99 116 92 101 99 1101E 72 11	11 98 102 99 Hone 92	: 110 90 97 99 noile	92 110 90 97 99 Hone 92 110 90	91 92 110 90 91 92	110 90 97 92 110 90 97 92 1	90 97 92 110 90 97	92 110 90	97 92 110 90 97 92 110	90 97 92	110 90 97 0	1 N HORE 1 2 N HORE 2 3 N HORE 2 3 N	at 3hrs indicate	5 N Hone 2	3 IN Hone 2 3 IN	none 2 5 N	none 2 3 N none 3ms 2	. pan
4 2 15.03.2021 SUMITA 39	2021/04/008756 RIGHT CA BREAST 10 5 95 115 92 100 98 none 95 115 92 100 96	none 95 115 92 100 96 none 95 115 92 100 96 none 96 1	12 90 97 96 none 95	5 115 92 100 96 none	95 115 92 100 96 none 95 115 92	100 95 115 92 100 95	115 92 100 95 115 92 100 95 1	115 92 100 95 115 92 100	95 115 92	100 95 115 92 100 95 115	92 100 95	115 92 100 0	1 N none 1 2 N none 2 3 N none 2 3 N	none 2 3 N none 5 6 Y 75mg 2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 2 3 N none 5hrs	2 pain
5 1 16.03.2021 PRAMOD KUMARI 36	2021/05/010231 RIGHT CA BREAST 15 4 74 136 105 115 100 none 74 136 105 115 100	none 74 136 105 115 100 none 74 136 105 115 100 none 78 15	32 106 115 100 none 74	1 136 105 115 100 none	74 136 105 115 100 none 74 136 105	115 74 136 105 115 74	136 105 115 74 136 105 115 74 1:	36 105 115 74 136 105 115	74 136 105	115 74 136 105 115 74 136	105 115 74	136 105 115 1	2 N none 1 2 N none 1 2 N none 2 3 N	Shrs   Shrs   Shrs   N   none   2   3   N   none   2   1   inidiclo   1   inidiclo   1   1   1   1   1   1   1   1   1	3 N none 2	3 N none 2 3 N	none 2 3 N	none 2 3 N none N/A N	A/A None
6 2 17.03.2021 BASANTI 51	2021/05/013018 RIGHT CA BREAST 10 4 76 115 92 100 97 none 76 115 92 100 97	none 76 115 92 100 97 none 76 115 92 100 97 none 77 1:	13 93 100 97 none 76	5 115 92 100 97 none	76 115 92 100 97 none 76 115 92	100 76 115 92 100 76	115 92 100 76 115 92 100 76 1	115 92 100 76 115 92 100	76 115 92	100 76 115 92 100 76 115	92 100 76	115 92 100 0	1 N none 1 2 N none 1 2 N none 2 3 N	none 2 3 N none 5 6 Y 75mg given at 2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 2 3 N none 6hrs	2 pain
7 1 18.03.2021 JUGNU DEVI 66	2021/05/011561 LEFT CA BREAST 0 0 64 118 96 103 100 none 64 118 96 103 100	) none 64 118 96 103 100 none 64 118 96 103 100 none 65 1:	17 97 104 100 none 64	1 118 96 103 100 none	64 118 96 103 100 none 64 118 96	103 64 118 96 103 98	128 82 97 110 147 112 124 102 1:	35 96 109 88 130 92 105	64 118 96	103 64 118 96 103 88 128	82 97 64	118 96 103 0	1 N none 1 2 N none 1 2 N none 2 3 N	none 2 3 N none 3 4 N none 6	7 Y inj diclo 75mg given 3	4 N none 2 3 N	none 2 3 N	none 2 3 N none 8hrs	2 Pain
8 2 19.03.2021 PISTA KANWAR 66 9 1 20.03.2021 LALKANWAR 66	2021/06/00/2036 LEFT CA BREAST 15 5 64 138 94 109 100 none 65 135 95 108 100 2021/06/00/2036 LEFT CA BREAST 10 5 64 137 94 108 100 none 65 135 95 108 100	0 none 64 134 95 85 100 none 65 135 98 87 100 none 66 13 0 none 64 134 95 85 100 none 65 135 98 87 100 none 66 13	32 98 86 100 none 66 35 99 86 100 none 66	5 135 96 109 100 none 5 135 96 109 100 none	65 135 97 109 100 none 64 134 95	108 64 134 95 108 82 108 64 134 95 108 82	143 95 111 69 130 92 105 65 11 143 95 111 69 130 92 105 65 11	34 94 107 64 135 95 108 34 94 107 64 135 95 108	64 135 94 64 135 94	108 65 136 96 109 65 135 108 65 136 96 109 65 135	96 109 66 96 109 65	135 96 109 0 135 96 109 1	1 N none 1 2 N none 1 2 N none 2 3 N 2 N none 1 2 N none 1 2 N none 2 3 N	N   N   N   N   N   N   N   N   N   N	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none 2 3 N		N/A None
10 2 21.03.2021 KOJA DEVI 45 11 2 22.03.2021 RUKSANA 66	2021/07/003010 RIGHT CA BREAST 10 5 64 136 95 109 100 none 64 138 94 109 100 2021/07/004322 LEFT CA BREAST 10 4 87 132 105 114 98 none 87 132 105 114 98	none   64   138   94   109   100   none   64   138   94   109   100   none   64   138   105   114   98   none   87   132   105   114   98   none   87   132   105   114   98   none   89   138   139	37 95 109 100 none 64 34 104 114 98 none 87	138 94 109 100 none 1 132 105 114 98 none	64 138 94 109 100 none 64 138 94 87 132 105 114 98 none 87 132 105	109 64 138 94 109 64 114 87 132 105 114 87	138 94 109 64 138 94 109 64 11 132 105 114 87 132 105 114 87 1	38 94 109 64 138 94 109 32 105 114 87 132 105 114	64 138 94 87 132 105	109 64 138 94 109 64 138 114 87 132 105 114 87 132	94 109 64 105 114 87	137 94 108 0 132 105 114 0	1 N none 2 3 N none 1 2 N none 2 3 N 1 N none 2 3 N none 1 2 N none 2 3 N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none 2 3 N none 2 3 N	none   2   3   N   none   N/A   N/	V/A None N/A None
12 1 25.03.2021 BHANWARI DEVI 40 13 2 24.03.2021 SEEMA KANWAR 39	2021/0/005109 LEFT CA BREAST 11 4 68 138 100 117 100 none 68 138 106 117 100 2021/08/005959 RIGHT CA BREAST 10 5 92 110 90 97 99 none 92 110 90 97 99	none   68   1.38   106   117   100   none   68   1.38   106   117   100   none   69   1.	37 107 117 100 none 68 12 92 99 99 none 92	2 110 90 97 99 none	92 110 90 97 99 none 92 110 90	97 92 110 90 97 92 110 90 97 92	138 106 117 68 1.8 106 117 68 1. 110 90 97 92 110 90 97 92 1	.38 106 117 68 1.38 106 117 10 90 97 92 110 90 97	92 110 90	97 92 110 90 97 92 110	90 97 92	138 106 117 0 110 90 97 1	1 N none 2 3 N none 1 2 N none 2 3 N 2 N none 1 2 N none 1 2 N none 2 3 N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2 inj diclo	3 N none 2 3 N 3 N none 2 3 N	none 2 3 N none 2 3 N	none   2   3   N   none   N/A   N/S	A None  N/A None
14 2 25.03.2021 VIMLA DEVI 36	2021/08/006122 RIGHT CA BREAST 10 4 95 115 92 100 98 none 95 115 92 100 96	none 95 115 92 100 96 none 95 115 92 100 96 none 96 115	17 97 104 96 none 95	5 115 92 100 96 none	95 115 92 100 96 none 95 115 92	100 95 115 92 100 95	115 92 100 95 115 92 100 95 1	115 92 100 95 115 92 100	95 115 92	100 95 115 92 100 95 115	92 100 95	115 92 100 0	1 N none 2 3 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         6	7 Y 75mg given 2 at 7hrs	3 N none 2 3 N	none 2 3 N	none 2 3 N none 7hrs 2	2 pain
15 1 26.03.2021 GEETA DEVI 51	2021/08/007471 RIGHT CA BREAST 10 4 74 136 105 115 100 none 74 136 105 115 100	0 none 74 136 105 115 100 none 74 136 105 115 100 none 77 13	34 102 113 100 none 74	3 136 105 115 100 none	74 136 105 115 100 none 74 136 105	115 74 136 105 115 74	136 105 115 74 136 105 115 74 1:	36 105 115 74 136 105 115	74 136 105	115 74 136 105 115 74 136	105 115 74	136 105 115 0	1 N none 2 3 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2	3 N none 2	3 N none 5 6 Y	75mg at 2 3 N	none 2 3 N none 16hrs 2	2 pain
16 1 27.03.2021 SANTOSH KANWAR 66 17 1 28.03.2021 MADHU DEVI 67	2021/08/007998 LEFT CA BREAST 10 5 76 115 92 100 97 none 76 115 92 100 97 2021/09/008560 LEFT CA BREAST 0 0 64 118 96 103 100 none 64 118 96 103 100	none   76   115   92   100   97   none   76   115   92   100   97   none   78   11   0	17 93 101 97 none 76 19 99 106 100 none 64	5 115 92 100 97 none 1 118 96 103 100 none	76 115 92 100 97 none 76 115 92 64 118 96 103 100 none 64 118 96	100 76 115 92 100 76 103 64 118 96 103 94	115 92 100 76 115 92 100 76 1 138 92 107 112 148 98 115 109 1	115 92 100 76 115 92 100 135 88 104 99 137 96 110	76 115 92 91 118 96	100 76 115 92 100 76 115 103 86 118 96 103 82 118	92 100 76 96 103 64	115 92 100 0 118 96 103 0	1 N none 2 3 N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         3         4         N         none         3	3 N none 2 4 N none 3	3 N none 2 3 N 4 N none 6 7 Y	none   2   3   N	none         2         3         N         none         N/A         N/A           none         3         4         N         none         15hrs         2	/A None 2 Pain
19 2 20022021 DIFFE 2017	201/00000031 DICHTCA DREAST 10 5 64 130 04 100 100	44 124 05 95 100 117 137 137	24 07 07	135 07 100 100	45 135 07 100 100	100	112 06 111 70 130 00 00 111	24 04 107 4	44 125	100 65 107 07	06 100	125		2 2 N	inj dielo	2 N	15hrs		2
10 2 29.03.2021 BIDYA SONI 66	2021070007231 KMHI CA BEEA31 10 3 04 136 94 109 100 none 65 135 95 108 100	1 Insure U-4 1.3-4 95 85 100 none 0.5 1.35 98 87 100 none 66 1.	59 100 none 66	90 109 100 none	0.3 1.35 97 109 100 none 64 1.34 95	100 04 1.54 95 108 82	111 09 130 92 105 65 E	24 107 04 135 95 108	04 135 94	100 00 135	90 109 65	1.55 90 109 1	2 N NONE 2 3 N NONE 2 3 N NONE 2 3 N	100 2 3 N none 2 3 N none 5	1 /5mg given 2 at 8hrs	3 N none 2 3 N	none 2 3 N	inj dielo N none Shrs 2	pain
19 1 30.03.2021 KAVITA DEVI 45	2021/09/011023 LEFT CA BREAST 15 4 64 138 94 109 100 none 65 135 95 108 100	) none 64 134 95 85 100 none 65 135 98 87 100 none 66 13	34 97 86 100 none 66	5 135 96 109 100 none	65 135 97 109 100 none 64 134 95	108 64 134 95 108 82	143 95 111 69 130 92 105 65 1:	34 94 107 64 135 95 108	64 135 94	108 65 136 96 109 65 135	96 109 65	135 96 109 0	1 N none 2 3 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2	3 N none 2	3 N none 2 3 N	none 5 6 Y	75mg at 2 3 N none 20hrs 2 20hrs inidiclo	2 pain
20 1 31.03.2021 MEERA DEVI 66	2021/09/011256 LEFT CA BREAST 10 5 64 138 94 109 100 none 64 138 94 109 100	none 64 138 94 109 100 none 64 138 94 109 100 none 66 13	39 96 110 100 none 64	138 94 109 100 none	64 138 94 109 100 none 64 138 94	109 64 138 94 109 64	138 94 109 64 138 94 109 64 1:	138 94 109 64 138 94 109	64 138 94	109 64 138 94 109 64 138	94 109 64	138 94 109 0	1 N none 2 3 N none 1 2 N none 2 3 N	none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 5 6 Y 75mg given at 21hrs	2 pain
21 2 01.04.2021 TARA DEVI 40	2021/09/012412 RIGHT CA BREAST 13 5 87 132 105 114 98 none 87 132 105 114 98	none         87         132         105         114         98         none         87         132         105         114         98         none         88         13	33 104 114 98 none 87	7 132 105 114 98 none	87 132 105 114 98 none 87 132 105	114 87 132 105 114 87	132 105 114 87 132 105 114 87 1:	32 105 114 87 132 105 114	87 132 105	114 87 132 105 114 87 132	105 114 87	132 105 114 0	1 N none 2 3 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2	3 N none 2	3 N none 2 3 N	none 2 3 N	21hrs	A/A none
22 1 02.04.2021 DHAPU DEVI 39	2021/10/012698 RIGHT CA BREAST 10 5 68 138 106 117 100 none 68 138 106 117 100	) none 68 138 106 117 100 none 68 138 106 117 100 none 67 13	37 108 118 100 none 68	3 138 106 117 100 none	68 138 106 117 100 none 68 138 106	117 68 138 106 117 68	138 106 117 68 138 106 117 68 1:	38 106 117 68 138 106 117	68 138 106	117 68 138 106 117 68 138	106 117 68	138 106 117 0	1 N none 2 3 N none 2 3 N none 2 3 N	none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 5 6 Y 75mg given at 22hrs	2 pain
23 1 03.04.2021 PARVESH RANI 36	2021/10013026 RIGHT CA BREAST 10 5 92 110 90 97 99 none 92 110 90 97 99	none 92 110 90 97 99 none 92 110 90 97 99 none 96 11	12 93 99 99 none 92	2 110 90 97 99 none	92 110 90 97 99 none 92 110 90	97 92 110 90 97 92	110 90 97 92 110 90 97 92 1	110 90 97 92 110 90 97	92 110 90	97 92 110 90 97 92 110	90 97 92	110 90 97 0	1 N none 1 2 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2	3 N none 2 inj diclo	3 N none 2 3 N	none 2 3 N	none 2 3 N none N/A N	A/A None
24 2 04.04.2021 RAMESWARI DEVI 51	2021/10013987 LEFT CA BREAST 10 4 95 115 92 100 98 none 95 115 92 100 96 2021/10014130 LEFT CA BREAST 15 4 74 136 105 115 100 none 74 136 105 115 100	none 95 115 92 100 96 none 95 115 92 100 96 none 96 11	14 94 101 96 none 95	5 115 92 100 96 none	95 115 92 100 96 none 95 115 92 74 136 105 115 100 none 74 136 105	100 95 115 92 100 95 115 74 136 105 115 74	115 92 100 95 115 92 100 95 1 136 105 115 74 136 105 115 74 1	115 92 100 95 115 92 100 136 105 115 74 136 105 115	95 115 92	100 95 115 92 100 95 115 115 74 136 105 115 74 136	92 100 95	115 92 100 1	2 N none 2 3 N none 4 5 N none 2 3 N	none 2 3 N none 2 3 N none 5	6 Y 75mg given 2 at 9hrs 2	3 N none 2 3 N	none 2 3 N	none 2 3 N none 9hrs 2	2 pain
26 1 06.04.2021 PUSPA DEVI 68	2021/10014221 LEFT CA BREAST 10 4 76 115 92 100 97 none 76 115 92 100 97	none 76 115 92 100 97 none 76 115 92 100 97 none 78 11	16 97 103 97 none 76	115 92 100 97 none	76 115 92 100 97 none 76 115 92	100 76 115 92 100 76	115 92 100 76 115 92 100 76 I	115 92 100 76 115 92 100	76 115 92	100 76 115 92 100 76 115	92 100 76	115 92 100 0	1 N none 2 3 N none 2 3 N none 2 3 N	None   2   3   N	3 N none 2	3 N none 2 3 N inj dielo	none 2 3 N	none 2 3 N none N/A N	#A None
27 2 07.04.2021 SHANTI DEVI 66	2021/10/014987 LEFT CA BREAST 10 4 64 118 96 103 100 none 64 118 96 103 100	) none 64 118 96 103 100 none 64 118 96 103 100 none 64 11	17 99 105 100 none 64	118 96 103 100 none	64 118 96 103 100 none 64 118 96	103 64 118 96 103 64	118 96 103 64 118 96 103 64 1	118 96 103 64 118 96 103	64 118 96	103 64 118 96 103 64 118	96 103 64	118 96 103 0	1 N none 2 3 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2	3 N none 5	6 Y 75mg 2 3 N given at 12hrs	none 2 3 N	none 2 3 N none 12hrs 2	2 pain
28 1 08.04.2021 KAMLA DEVI 67	2021/11/015421 RIGHT CA BREAST 10 5 66 138 94 109 100 none 65 135 95 108 100	0 none 64 134 95 85 100 none 68 135 98 87 100 none 66 13	34 97 86 108 none 66	135 96 109 100 none	65 135 97 109 100 none 64 134 95	108 64 134 95 108 82	143 95 111 69 130 92 105 65 11 142 05 111 60 130 92 105 65 11	34 94 107 64 135 95 108	64 135 94	108 65 136 96 109 65 135	96 109 65	135 96 109 0	1 N none 1 2 N none 2 3 N none 2 3 N	none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N inj diclo	none 2 3 N none N/A N/	JA None
30 2 10.04.2021 VIMLA BISHNOI 45	2021/11/015399 LEPT CA BREAST 10 5 64 137 96 110 100 none 65 135 95 108 100	100 none 64 134 95 85 100 none 65 135 98 87 100 none 69 13	34 97 86 108 none 66	5 135 96 109 100 none	65 135 97 109 100 none 64 134 95	108 64 134 95 108 82	143 95 111 69 130 92 105 65 II	34 94 107 64 135 95 108	64 135 94	108 65 136 96 109 65 135	96 109 65	135 96 109 1	2 N none 2 3 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2           2         3         N         none         2         3         N         none         2	3 N none 2	3 N none 2 3 N	16hrs none 2 3 N		N/A None
31 2 11.04.2021 JHAMRUDI DEVI 66 32 2 12.04.2021 MIRZA KHATUN 40 33 1 13.04.2021 HEMI ATA BANO 39	2021/11/01/987 RIGHT CA BREAST 10 4 72 132 95 107 100 none 64 138 94 109 100 2021/11/01/210 RIGHT CA BREAST 10 4 87 132 105 114 98 none 87 132 105 114 98 2021/11/01/245 RIGHT CA BREAST 15 5 68 138 106 117 100 none 68 138 1	0 none 64 138 94 109 100 none 64 138 94 109 100 none 71 12 none 87 132 105 114 98 none 87 132 105 114 98 none 88 12 none 68 138 106 117 100 none 70 12	38 94 109 100 none 64 32 105 114 98 none 87 38 106 117 100 none 68	138 94 109 100 none 132 105 114 98 none 138 106 117 100 none	64 138 94 109 100 none 64 138 94 87 132 105 114 98 none 87 132 105 68 138 106 117 100 none 68 138 106	109 64 138 94 109 64 114 87 132 105 114 87 117 68 138 106 117 68	138 94 109 64 138 94 109 64 1: 132 105 114 87 132 105 114 87 132 187 114 87 138 106 117 68 138 138 106 117 68 138 138 138 138 138 138 138 138 138 13	38 94 109 64 138 94 109 32 105 114 87 132 105 114 38 106 117 68 138 106 117	64 138 94 87 132 105 68 138 106	109 64 138 94 109 64 138 114 87 132 105 114 87 132 117 68 138 106 117 68 138	94 109 64 105 114 87 106 117 68	138 94 109 0 132 105 114 0 138 106 117 0	1 N none 2 3 N 1 N none 2 3 N none 2 N none	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N 3 N none 2 3 N	none   2   3   N	none   2   3   N   none   N/A   N/   none   2   3   N   none   N/A   N     N   N   N   N   N   N   N   N	/A None  N/A None  N/A None
34 1 14.04.2021 MEENA CHOUHAN 36	2021/12/017965 LEFT CA BREAST 10 5 92 110 90 97 99 none 92 110 90 97 99	none 92 110 90 97 99 none 92 110 90 97 99 none 92 110 110 90 97 99 none 98 11	10 90 97 99 none 92	2 110 90 97 99 none	92 110 90 97 99 none 92 110 90	97 92 110 90 97 92	110 90 97 92 110 90 97 92 1	90 97 92 110 90 97	92 110 90	97 92 110 90 97 92 110	90 97 92	110 90 97 0	1 N none 2 3 N none 0 1 N none 2 3 N	none         2         3         N         none         2         3         N         none         2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 2 3 N none N/A N/ inj diclo	JA None
35 2 15.04.2021 PINTU DEVI 51	2021/12/018066 LEFT CA BREAST 10 5 95 115 92 100 98 none 95 115 92 100 96	none 95 115 92 100 96 none 95 115 92 100 96 none 99 1:	15 92 100 96 none 95	5 115 92 100 96 none	95 115 92 100 96 none 95 115 92	100 95 115 92 100 95	115 92 100 95 115 92 100 95 1	115 92 100 95 115 92 100	95 115 92	100 95 115 92 100 95 115	92 100 95	115 92 100 1	2 N none 2 3 N none 5 6 N none 4 5 N	none 3 4 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 5 6 Y 3mg given at 21hrs 2 21hrs 2	2 pain
36 1 16.04.2021 SONALI DEVI 66 37 1 17.04.2021 SAROJ 66 38 2 18.04.2021 BINDU SHARMA 66	2021/12/018252 RIGHT CA BREAST 10 5 74 136 105 115 100 none 74 136 105 115 100 2021/12/01878 LEFT CA BREAST 10 4 76 115 92 100 97 none 76 115 92 100 97 2021/12/018954 LEFT CA BREAST 10 4 64 118 96 103 100 none 64 118 118 96 103 100 none 64 118 118 96 103 100 none 64 118 118	) none 74 136 105 115 100 none 74 136 105 115 100 none 77 12 none 76 115 92 100 97 none 76 115 92 100 97 none 79 11	36 105 115 100 none 74 15 92 100 97 none 76 18 96 103 100 none 64	136 105 115 100 none 115 92 100 97 none 118 96 103 100 none	74 136 105 115 100 none 74 136 105 76 115 92 100 97 none 76 115 92 64 118 96 103 100 none 64 118 96	115 74 136 105 115 74 100 76 115 92 100 76 103 64 118 96 103 64	136   105   115   74   136   105   115   74   13   115   92   100   76   115   92   100   76   1   118   96   103   64   118   96   103   64   1	36 105 115 74 136 105 115 115 92 100 76 115 92 100 118 96 103 64 118 96 103	74 136 105 76 115 92 64 118 96	115 74 136 105 115 74 136 100 76 115 92 100 76 115 103 64 118 96 103 64 118	105 115 74 92 100 76 96 103 64	136 105 115 0 115 92 100 0 118 96 103 0	1 N none 2 3 N none 2 3 N none 2 3 N none 2 3 N 1 N 1 N none 2 3 N none 2 3 N none 2 3 N N none 2 N none 2 N N N N N N N N N N N N N N N N N N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N 3 N none 2 3 N	none   2   3   N	none   2   3   N   none   N/A   N/     none   2   3   N   none   N/A   F     none   2   3   N   none   N/A   F	/A None  N/A None  N/A None
39 1 19.04.2021 TEJA DEVI 45 40 1 20.04.2021 PARU DEVI 66	2021/12/019123 RIGHT CA BREAST 10 5 64 138 94 109 100 none 65 135 95 108 100 2022/01/000698 RIGHT CA BREAST 10 4 64 138 94 109 100 none 65 135 95 108 100	0 none 64 134 95 85 100 none 65 135 98 87 100 none 69 13 0 none 64 134 95 85 100 none 65 135 98 87 100 none 69 13	34 97 86 100 none 66 34 97 86 100 none 66	5 135 96 109 100 none 5 135 96 109 100 none	65 135 97 109 100 none 64 134 95 65 135 97 109 100 none 64 134 95	108         64         134         95         108         82           108         64         134         95         108         82           108         64         134         95         108         82	143 95 111 69 130 92 105 65 11 143 95 111 69 130 92 105 65 11	34 94 107 64 135 95 108 34 94 107 64 135 95 108	64 135 94 64 135 94	108 65 136 96 109 65 135 108 65 136 96 109 65 135	96 109 65 96 109 65	135 96 109 1 135 96 109 0	2 N none 2 3 N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none 2 3 N none 2 3 N		d/A None N/A None
41 2 21.04.2021 KAUSHALYA KAKKAR 40	2022/01/001547 RIGHT CA BREAST 10 4 64 138 94 109 100 none 65 135 95 108 100	0 none 64 134 95 85 100 none 65 135 98 87 100 none 66 13 0 none 64 138 94 109 100 none 64 138 94 109 100 none 67 13	34 97 86 100 none 66	5 135 96 109 100 none	65 135 97 109 100 none 64 134 95	108 64 134 95 108 82	143 95 111 69 130 92 105 65 1: 138 94 109 64 138 94 109 64 1:	34 94 107 64 135 95 108 38 94 109 64 138 94 109	64 135 94	108 65 136 96 109 65 135	96 109 65	135 96 109 0	1 N none 2 3 N none 4 5 N none 2 3 N	none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 2 3 N none N/A N	V/A None
43 2 23.04.2021 PARU DEVI 36 44 1 24.04.2021 PRAMILA 51	2022/01/002/01 LEFT CA BREAST 15 4 87 132 105 114 98 none 88 135 101 112 98 2022/01/002/198 LEFT CA BREAST 10 5 68 138 106 117 100 none 65 135 95 108 100	1   10   10   10   10   10   10   10	32 105 114 98 none 87 38 106 117 100 none 68	7 132 105 114 98 none 3 138 106 117 100 none	87 132 105 114 98 none 87 132 105 68 138 106 117 100 none 68 138 106	114 87 132 105 114 87 117 68 138 106 117 68	132 105 114 87 132 105 114 87 13 138 106 117 68 138 106 117 68 1	32 105 114 87 132 105 114 38 106 117 68 138 106 117	87 132 105 68 138 106	114 87 132 105 114 87 132 117 68 138 106 117 68 138	105 114 87 106 117 68	132 105 114 0 138 106 117 0	1 N none 1 2 N none 2 3 N none 2 3 N none 2 3 N 1	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none   2   3   N		J/A None N/A None
45 2 25.04.2021 PARVATI DEVI 66 46 2 26.04.2021 SUSHILA BHATI 68	2022/02/002245 LEFT CA BREAST 10 4 92 110 92 110 90 none 99 115 90 98 99 2022/02/002381 LEFT CA BREAST 10 5 95 115 92 100 98 none 92 110 90 97 96	none         93         116         93         101         99         none         92         110         90         97         99         none         99         11           none         95         115         92         100         96         none         95         115         92         100         96         none         97         11	10 90 97 99 none 92 15 92 100 96 none 95	2 110 90 97 99 none 5 115 92 100 96 none	92 110 90 97 99 none 92 110 90 95 115 92 100 96 none 95 115 92	97 92 110 90 97 92 110 95 115 92 100 95	110 90 97 92 110 90 97 92 1 115 92 100 95 115 92 100 95 1	110 90 97 92 110 90 97 115 92 100 95 115 92 100	92 110 90 95 115 92	97 92 110 90 97 92 110 100 95 115 92 100 95 115	90 97 92 92 100 95	110 90 97 0 115 92 100 1	1 N none 1 2 N none 4 5 N none 2 3 N 2 N none 1 2 N none 2 3 N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none         2         3         N           none         2         3         N	none   2   3   N   none   N/A   N/   none   2   3   N   none   N/A   Y	JA None N/A None
48 2 28 04 2021 PRAMU DEVI 67	202202002452 RIGHT CA BREAST 10 5 76 115 92 100 97 none 77 120 99 106 97	none 76 115 92 100 97 none 76 115 92 100 97 none 76 115 92 100 97 none 79 11	15 92 100 97 pone 76	115 92 100 97 none	74 130 103 113 100 100e 74 130 103	110 76 115 92 100 76	150 103 113 74 150 103 113 74 1.	115 92 100 76 115 92 100	76 115 92	113	92 100 76	115 92 100 0	1 N none 1 2 N none 2 3 N none 2 3 N	none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 5 6 Y 75mg 23hrs	2 pain
49 1 29.04.2021 KAMOD KANWAR 66	2022/03/003015 LEFT CA BREAST 10 5 64 118 96 103 100 none 68 118 96 103 100	) none 64 118 96 103 100 none 64 118 96 103 100 none 66 11	18 96 103 100 none 64	118 96 103 100 none	64 118 96 103 100 none 64 118 96	103 64 118 96 103 64	118 96 103 64 118 96 103 64 1	118 96 103 64 118 96 103	64 118 96	103 64 118 96 103 64 118	96 103 64	118 96 103 0	1 N none 1 2 N none 2 3 N none 2 3 N	none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N	1   1   2   3   N     none   N/A	N/A None
50 2 30.04.2021 SUNITA GARG 45 51 1 01.05.2021 GANGA DEVI 66	2022/03/003118         RIGHT CA BREAST         10         4         68         138         94         109         100         none         65         135         95         108         100           2022/03/003618         RIGHT CA BREAST         10         4         67         132         95         107         100         none         72         135         95         108         100           100 <td>0 none 76 134 95 85 100 none 65 135 98 87 108 none 69 13 0 none 77 134 95 85 100 none 65 135 98 87 108 none 66 13</td> <td>34 97 86 100 none 66 34 97 86 100 none 66</td> <td>135 96 109 100 none 135 96 109 100 none</td> <td>65 135 97 109 100 none 64 134 95 65 135 97 109 100 none 64 134 95</td> <td>108         64         134         95         108         82           108         64         134         95         108         82           108         64         134         95         108         82</td> <td>143         95         111         69         130         92         105         65         11           143         95         111         69         130         92         105         65         11           143         95         111         69         130         92         105         65         11</td> <td>34 94 107 64 135 95 108 34 94 107 64 135 95 108</td> <td>64 135 94 64 135 94</td> <td>108         65         136         96         109         65         135           108         65         136         96         109         65         135           108         65         136         96         109         65         135</td> <td>96 109 65 96 109 65</td> <td>135 96 109 0 135 96 109 0</td> <td>1         N         none         2         3         N         none         2         3         N         none         2         3         N           1         N         none         2         3         N         none         0         1         N         none         2         3         N</td> <td>none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2</td> <td>3 N none 2 3 N none 2</td> <td>3 N none 2 3 N 3 N none 2 3 N</td> <td>none         2         3         N           none         2         3         N</td> <td>none         2         3         N         none         N/A         N'           none         2         3         N         none         N/A         7'</td> <td>i/A None N/A None</td>	0 none 76 134 95 85 100 none 65 135 98 87 108 none 69 13 0 none 77 134 95 85 100 none 65 135 98 87 108 none 66 13	34 97 86 100 none 66 34 97 86 100 none 66	135 96 109 100 none 135 96 109 100 none	65 135 97 109 100 none 64 134 95 65 135 97 109 100 none 64 134 95	108         64         134         95         108         82           108         64         134         95         108         82           108         64         134         95         108         82	143         95         111         69         130         92         105         65         11           143         95         111         69         130         92         105         65         11           143         95         111         69         130         92         105         65         11	34 94 107 64 135 95 108 34 94 107 64 135 95 108	64 135 94 64 135 94	108         65         136         96         109         65         135           108         65         136         96         109         65         135           108         65         136         96         109         65         135	96 109 65 96 109 65	135 96 109 0 135 96 109 0	1         N         none         2         3         N         none         2         3         N         none         2         3         N           1         N         none         2         3         N         none         0         1         N         none         2         3         N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none         2         3         N           none         2         3         N	none         2         3         N         none         N/A         N'           none         2         3         N         none         N/A         7'	i/A None N/A None
52 2 02.05.2021 BINA TIWARI 40 53 1 03.05.2021 SOHANI DEVI 39 54 2 04.05.2021 MITTU DEVI 36	2022/03/004/025 RIGHT CA BREAST 15 4 73 133 99 110 100 none 71 135 95 108 100 2022/03/004/15 LEFT CA BREAST 10 4 64 136 94 108 100 none 64 138 94 109 100 2022/03/004/15 LEFT CA BREAST 10 5 87 132 105 114 98 none 87 132 105 114 98	0 none 72 138 95 85 100 none 65 135 98 87 108 none 66 13 0 none 69 141 94 110 100 none 64 138 94 109 108 none 71 13 none 92 132 108 116 99 none 87 132 105 114 98 none 89 17	34 97 86 100 none 66 38 94 109 100 none 64 32 105 114 98 none 87	5 135 96 109 100 none 1 138 94 109 100 none 1 132 105 114 98 none	65 135 97 109 100 none 64 134 95 64 138 94 109 100 none 64 138 94 87 132 105 114 98 none 87 132 105	108 64 134 95 108 82 109 64 138 94 109 64 114 87 132 105 114 87	143 95 111 69 130 92 105 65 11 138 94 109 64 138 94 109 64 1 132 105 114 87 132 105 114 87	34 94 107 64 135 95 108 38 94 109 64 138 94 109 32 105 114 87 132 105 114	64 135 94 64 138 94 87 132 105	108 65 136 96 109 65 135 109 64 138 94 109 64 138 114 87 132 105 114 87 132	96 109 65 94 109 64 105 114 87	135 96 109 1 138 94 109 0 132 105 114 0	2 N none 2 3 N 1 N none 2 3 N none 2 N n	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N 3 N none 2 3 N	none 2 3 N none 2 3 N	none 2 3 N none N/A N// none 2 3 N none N/A N/ none 2 3 N none N/A N none 2 3 N none N/A	A None N/A None N/A None
55 1 05.05.2021 MANGI DEVI 51 56 2 06.05.2021 INDU BALA 66	2022/04/04/04812 LEFT CA BREAST 10 5 68 138 106 117 100 none 68 138 106 117 100 2022/04/04/04/01 LEFT CA BREAST 13 5 92 110 90 97 99 none 92 110 90 97 99	0 none 69 138 106 117 100 none 72 138 106 117 100 none 68 11 none 99 110 90 97 99 none 92 110 90 97 99 none 92 110 90 97 99 none 99 1	38 106 117 100 none 68 10 90 97 99 none 92	3 138 106 117 100 none 2 110 90 97 99 none	68 138 106 117 100 none 68 138 106 92 110 90 97 99 none 92 110 90	117 68 138 106 117 68 97 92 110 90 97 92	138 106 117 68 138 106 117 68 13 110 90 97 92 110 90 97 92 1	38 106 117 68 138 106 117 10 90 97 92 110 90 97	68 138 106 92 110 90	117 68 138 106 117 68 138 97 92 110 90 97 92 110	106 117 68 90 97 92	138 106 117 0 110 90 97 0	1 N none 2 3 N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none 2 3 N none 2 3 N		d/A None N/A None
57 2 07.05.2021 RUKSANA 66 58 1 08.05.2021 BASANTI 66	202204005098 RIGHT CA BREAST 10 4 95 115 92 100 98 none 95 115 92 100 96 202204005745 LEFT CA BREAST 10 4 74 136 105 115 100 none 77 136 105 115 100 000 000 000 000 000 000 000	none         95         115         92         100         96         none         98         115         92         100         96         none         95         11           0         none         74         136         105         115         100         none         78         136         105         115         100         none         74         12	15 92 100 96 none 95 36 105 115 100 none 74	5 115 92 100 96 none 1 136 105 115 100 none	95 115 92 100 96 none 95 115 92 74 136 105 115 100 none 74 136 105 105 105 105 105 105 105 105 105 105	100 95 115 92 100 95 115 74 136 105 115 74	115 92 100 95 115 92 100 95 1 136 105 115 74 136 105 115 74 11	115 92 100 95 115 92 100 36 105 115 74 136 105 115	95 115 92 74 136 105	100 95 115 92 100 95 115 115 74 136 105 115 74 136	92 100 95 105 115 74	115 92 100 0 136 105 115 1	1 N none 1 2 N none 2 3 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2           2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none         2         3         N           none         2         3         N	none   2   3   N   none   N/A   N/   none   2   3   N   none   N/A   Y	JA None N/A None
59 1 09.03.2021 SONU KANWAK 45 60 2 10.05.2021 RAMESWARI DEVI 66 61 1 11.05.2021 MAYA DEVI 40	20220/5006694 LEFT CA BREAST 10 5 64 118 96 103 100 none 64 118 96 103 100 2020/5006925 LEFT CA BREAST 10 5 64 118 94 109 100 none 65 135 95 108 100	18/18   70   115   92   100   97   100cc   78   115   92   100   97   100cc   76   11	1.5 9.2 10.0 97 none 76 18 96 10.3 100 none 64 34 97 86 100 none 66	92 100 97 none 1 118 96 103 100 none 5 135 96 109 100 none	113   92   100   97   none   76   115   92   96   118   96   103   100   none   64   118   96   65   135   97   109   100   none   64   134   95	100 /0 115 92 100 76 103 64 118 96 103 64 108 64 134 95 108 82	113 92 100 76 115 92 100 76 1 118 96 103 64 118 96 103 64 1 143 95 111 69 130 92 105 65 1:	115 22 100 70 115 92 100 118 96 103 64 118 96 103 34 94 107 64 135 95 108	64 118 96 64 135 94	103	96 103 64 96 109 65	115 92 100 0 118 96 103 0 135 96 109 0	1	18/11   2   3   N   100nc   2   3   N   100nc   2   1	3 N none 2 3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none   2   3   N	N   N   N   N   N   N   N   N   N   N	None
62 2 12.05.2021 SAJANA DEVI 39 63 1 13.05.2021 SUNITA DEVI 36 64 2 14.05.2021 HANIEA BARII 51	202205007132 LEFT CA BREAST 14 5 64 138 94 109 100 none 65 135 95 108 100 202205007255 RIGHT CA BREAST 10 4 64 138 94 109 100 none 64 138 94 109 100 none 64 138 94 109 100		34 97 86 100 none 66 38 94 109 100 none 64 32 105 114 98 000 97	135 96 109 100 none 1 138 94 109 100 none 1 132 105 114 00	65 135 97 109 100 none 64 134 95 64 138 94 109 100 none 64 138 94 109 100 none 64 138 94 109 100 none 64 138 94 109 106 114 09 none 64 138 94	108 64 134 95 108 82 109 64 138 94 109 64 114 87 132 105 114 97	143 95 111 69 130 92 105 65 11 138 94 109 64 138 94 109 64 11 132 105 114 87 133 105 114 87	34 94 107 64 135 95 108 38 94 109 64 138 94 109 32 105 114 87 122 105	64 135 94 64 138 94 87 122 105	108 65 136 96 109 65 135 109 64 138 94 109 64 138 114 87 132 105 114 87 122	96 109 65 94 109 64 105 114 87	135 96 109 1 138 94 109 0	2 N none 2 3 N none 2 3 N none 2 3 N none 2 3 N none 2 1 N none 2 N none	none         2         3         N         none         2         3         N         none         2           none         2         3         N         none         2         3         N         none         2           2         3         N         none         2         3         N         none         2	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none 2 3 N none 2 3 N	none   2   3   N   none   N/A   N/   none   2   3   N   none   N/A   7     none   2   3   N   none   N/A   7	/A None N/A None N/A None
65 1 15.05.2021 KAMALA DEVI 66	2022/06/007465 LEFT CA BREAST 14 5 68 138 106 117 100 none 68 138 106 117 100	0 none 68 138 106 117 100 none 68 138 106 117 100 none 67 12	38 106 117 100 none 68	8 138 106 117 100 none	68 138 106 117 100 none 68 138 106	117 68 138 106 117 68	138 106 117 68 138 106 117 68 1	38 106 117 68 138 106 117	68 138 106	117 68 138 106 117 68 138	106 117 68	138 106 117 0	1 N none 2 3 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2	3 N none 2	3 N none 2 3 N	none 2 3 N	none   2   3   N   none   N/A   N	i/A None
66 2 16.05.2021 CHUKI DEVI 68	2022/06/008023 RIGHT CA BREAST 10 4 92 110 90 97 99 none 92 110 90 97 99	none   92   110   90   97   99   none   92   110   90   97   99   none   94   11	10 90 97 99 none 92	2 110 90 97 99 none	92 110 90 97 99 none 92 110 90	97 92 110 90 97 92	110 90 97 92 110 90 97 92 1	110 90 97 92 110 90 97	92 110 90	97 92 110 90 97 92 110	90 97 92	110 90 97 0	1 N none 1 2 N none 2 3 N none 2 3 N	none         2         3         N         none         2         3         N         none         2	3 N none 2	3 N none 2 3 N	none 2 3 N	none 5 6 Y 75mg given at 24hrs 24hrs	2 pain
67 2 17.05.2021 PRIYANTA VAISHNAV 66	2022/06/08225 RIGHT CA BREAST 10 4 95 115 92 100 98 none 95 115 92 100 96	none 95 115 92 100 96 none 95 115 92 100 96 none 98 1:	15 92 100 96 none 95	115 02 100 06 pope	95 115 92 100 96 2020 95 115 92	100 95 115 92 100 95	115 92 100 95 115 92 100 95 1	115 92 100 95 115 92 100	05 115 02	100 95 115 92 100 95 115	92 100 95	115 92 100 1	2 N pope 2 2 N pope 2 2 N pope 2 2 N	pope 2 3 N pope 2 3 N pope 2	3 N none 2	2 N none 2 2 N	none 2 3 N	none 2 3 N none N/A N	J/A None
69 2 19.05.2021 BHAGWATI 66 70 1 20.05.2021 RAJIYA BANO 45	2022/07/09/117 RIGHT CA BREAST 10 5 64 118 96 103 100 none 64 118 96 103 100		15 92 100 97 none 74 18 96 103 100 none 64	103 115 100 none 115 92 100 97 none 118 96 103 100 none	76 115 92 100 97 none 76 115 92 64 118 96 103 100 none 64 118 96	100 76 115 92 100 76 103 64 118 96 103 64	115 92 100 76 115 92 100 76 1 118 96 103 64 118 96 103 64 1	115 92 100 76 115 92 100 118 96 103 64 118 96 103	76 115 92 64 118 96	100 76 115 92 100 76 115 103 64 118 96 103 64 118	92 100 76 96 103 64	115 92 100 0 118 96 103 0	1 N none 1 2 N none 2 3 N none 2 3 N none 2 3 N none 1 N none 2 3 N none 2 N N N N none 2 N N N N N N N N N N N N N N N N N N	N   N   N   N   N   N   N   N   N   N	3 N none 2 3 N none 2	3 N none 2 3 N 3 N none 2 3 N	none   2   3   N	N   N   N   N   N   N   N   N   N   N	J/A None N/A None
71 2 21.05.2021 JETHI DEVI 66	2022/07/009354 RIGHT CA BREAST 10 4 68 138 94 109 100 none 69 138 99 112 100	1.15   52   100   115   125   100   115   125   100   115   125	34 97 86 100 none 66	5 135 96 109 100 none	65 135 97 109 100 none 64 134 95	108 64 134 95 108 82	143 95 111 69 130 92 105 65 E	34 94 107 64 135 95 108	64 135 94	108 65 136 96 109 65 135	96 109 65	135 96 109 1	2 N none 2 3 N none 2 3 N none 2 3 N	none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 5 6 Y	inj diclo 75mg given at 2	2 pain
72 1 22.05.2021 BHAGWATI KASHYAP 40	2022/08/009778 LEFT CA BREAST 10 5 66 141 96 111 100 none 65 135 95 108 100	) none 71 134 95 85 100 none 65 135 98 87 100 none 69 13	34 97 86 100 none 66	5 135 96 109 100 none	65 135 97 109 100 none 64 134 95	108 64 134 95 108 82	143 95 111 69 130 92 105 65 E	34 94 107 64 135 95 108	64 135 94	108 65 136 96 109 65 135	96 109 65	135 96 109 0	1 N none 2 3 N none 2 3 N none 2 3 N	none 2 3 N none 2 3 N none 2	3 N none 2	3 N none 2 3 N	none 2 3 N	18hrs	N/A None
												1 1 2							